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ABSTRACT
NOVEL MECHANISMS AND BIOMARKERS IN ALCOHOL-INDUCED ORGAN
INJURY

Christine E. Dolin
April 12, 2019

Background. Ethanol (EtOH) consumption is known to affect multiple organs;
this is unsurprising, as the concentration of EtOH in the blood at relevant doses
reaches the millimolar range. The overarching goal of this dissertation was to
elucidate mechanisms of alcohol-induced organ injury, specifically the effects of
alcohol on the hepatic extracellular matrix (ECM) proteome, the alcoholic
hepatitis (AH) plasma peptidome, and the effects of alcohol on the renal cortex
proteome and transcriptome. Methods. Mice were pair-fed ethanol-containing
liquid diet chronically, and then some mice were administered lipopolysaccharide
(LPS). Liver sections from these mice were processed in a series of increasingly
rigorous extraction buffers to separate proteins by ‘age’ and crosslinking.
Extracted proteins were identified using liquid chromatography-tandem mass
spectrometry (LC-MS/MS). For the AH study, a workflow was developed for the
peptidomic analysis of plasma from healthy participants or AH patients. AH
severity was stratified by MELD score as mild (<12; n=45), moderate (12-19;
vi

n=23) or severe (>19; n=37). The peptidome in AH and control plasma was
analyzed with LC-MS/MS. For the kidney study, renal cortex proteins were
extracted in lysis buffer, and RNA was also isolated. Extracted proteins were
identified using LC-MS/MS, and RNA sequencing (i.e. transcriptomics) identified
transcripts. Results. Chapter III introduced a new proteomic approach for
characterizing the hepatic matrisome, which demonstrated that the hepatic
matrisome responds dynamically to both acute (LPS) and chronic (ethanol)
stresses, long before more dramatic fibrotic changes to the liver. Chapter IV
demonstrated that AH causes detectable changes in the plasma ECM
degradome/peptidome of patients, and that the LC-MS/MS analysis of the
plasma peptidome is a novel, minimally-invasive method for prognosis
stratification in patients with AH. Finally, Chapter V revealed that chronic,
moderate ethanol consumption affects renal cortical oxidant response pathways
at the protein and transcript level. Conclusions. The work presented in this
dissertation has, in conclusion, revealed that the hepatic ECM responds
dynamically to stress, plasma peptides, including ECM peptides, change with AH
severity, and chronic ethanol consumption affects renal cortical oxidant response
pathways.
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CHAPTER I

INTRODUCTION

A.

Background and rationale for this study

1. Alcohol consumption and human health
Alcoholic beverages were valued in ancient cultures as an antimicrobial
agent, a source of hydration and nourishment, as well as a “social lubricant” (1).
Today, alcohol consumption is nearly ubiquitous worldwide. In the United States
alone, 86.4% of adults report consuming alcohol at some point in their lives (2).
Just as alcohol use is common worldwide, so is alcohol abuse. Chronic,
compulsive alcohol abuse characterizes clinically recognized alcohol use
disorder (AUD), which is defined with specific criteria in the Diagnostic and
Statistical Manual of Mental Disorders (DSM). AUDs affect approximately 15
million adults in the United States (2). Worldwide, an estimated 64 million people
are dependent on alcohol (3).
While AUD is, in itself, a brain disorder, the serious health consequences
of alcohol abuse are much more extensive. In addition to the brain (4), chronic
alcohol consumption/abuse directly damages several organs, including the liver
(5), lung (6), skeletal muscle and heart (7), and pancreas (8). Alcohol
1

consumption is a risk factor for over 200 health conditions (9). Alcohol
consumption accounts for ~6% of all disability-adjusted life years lost in the
United States, and alcohol-related disease and disability costs the United States
approximately 250 billion dollars annually (2). There is a great need for
mechanism-based therapies to treat and/or protect against alcohol-induced
organ damage, especially given the high rate of relapse of AUDs (10).
Unfortunately, current therapies for alcohol-induced organ damage are palliative,
at best, and do not prevent or reverse the progression of organ injuries. The
overarching goal of this project is to develop such means of detection and
treatment of alcohol-induced end organ damage.

2. The extracellular matrix: more than a scaffold
The extracellular matrix (ECM) is a non-cellular three-dimensional scaffold
within all tissues and organs (11) that is critical for structure and cell signaling.
Genetic mutations in matrix components can cause a myriad of connective tissue
pathologies (12-14), if not embryonic lethality (15, 16). Therefore, the ECM is
essential to normal tissue homeostasis.
The most obvious function of the ECM is to physically support cells and
thereby provide structure to tissue. The composition of the ECM allows for its
structural role. A network of collagens, which provides tensile strength, is a
major component of the ECM of the basement membranes and interstitial
matrices in all physiological domains (17). In all solid organs, fibroblasts secrete
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fibrous glycoproteins and proteoglycans that adhere to this collagen scaffold in a
highly cross-linked meshwork (17).
In addition to its structural role, the ECM can also play a role in cell signaling.
The heparin and heparan sulfate components of many proteoglycans readily bind
soluble growth factors, cytokines, and chemokines and can even regulate their
activation and presentation to cells (18). Additionally, these signaling molecules
can become spatially distributed and form gradients by binding to the ECM (18).
These gradients are important for tissue development and inflammatory cell
migration (18).
In addition to binding signaling molecules, ECM proteins can directly engage
in signaling. Indeed, ECM proteins are ligands of cell surface receptors,
including integrins, which bind specific ECM protein domains (e.g., the RGD
motif) (19). Through interaction with cell-surface receptors, the ECM can activate
intracellular signaling (19)
The ECM is far from static; it is full of activities required to maintain
homeostasis or (mal)adapt to insult. Proteases and protease inhibitors are key
players in maintaining and regulating other ECM components (20). Proteases
may deposit (e.g., proteases involved in the complement and coagulation
cascades) or degrade (e.g. matrix metalloproteinases, MMPs) matrix
components to facilitate rapid changes in ECM organization. Alterations in the
extracellular landscape, including changes in ECM topography, crosslinking, and
biochemistry, can affect cell migration, adhesion, and activation (21). Indeed,
protease-mediated modification of the ECM can have physical and/or
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biochemical significance. For example, ECM proteolytic degradation can create
physical space through which cells can migrate (22). Alternatively, ECM
proteolysis can expose or remove binding sites; for example, protease cleavage
of laminin-5 exposes integrin-binding sites that are necessary for cell adhesion
(23). Proteases can also contribute to ECM dynamics by modulating the activity
of other enzymes (e.g., proteinase precursors (24) and soluble mediators (e.g.,
IL-8, (21)). Degradation of ECM components, such as the glycosaminoglycan
components of proteoglycans, can release growth factors (18). The broad,
consequential activity of proteases necessitates intricate, and often redundant,
mechanisms of regulation. Indeed, proteases are not only regulated at the levels
of transcription and secretion, but also at the level of activity (25). Proteases are
often activated through cleavage by another protease, and can be targeted by
inhibitors, such as tissue inhibitors of matrix metalloproteinases (TIMPs) (22).
Therefore, regulation of the ECM is important for the function of tissues and
organs.

3. The role of the ECM in inflammation and disease
As previously discussed, tight regulation of the ECM is critical for normal
tissue homeostasis. Such regulation also facilitates rapid changes that allow the
ECM to play a dynamic and responsive role during inflammation and tissue
repair. Perturbations in the ECM during either of these physiological states can
contribute to disease initiation and progression. Indeed, ECM dysregulation is
often a hallmark of tissue pathology (16).
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During hepatic inflammation of any cause, hepatocytes express many
different chemokines and inflammatory mediators (26). During hepatocyte injury
or death, they also release damage-associated molecular patterns (DAMPs),
which activate resident macrophages (Kupffer cells, KCs). Additionally,
pathogen-associated molecular patterns (PAMPs, e.g. LPS) activate pattern
recognition receptors (PRRs) (27). DAMPs and PAMPs cause the release of
cytokines and acute phase proteins (APPs), such as TNFα, IL-1, IL-6. Hepatic
stellate cells become activated, and deposit new ECM and alter matrix
degradation. Although this response is important for normal
immune/inflammatory function, dysregulation of this response can cause
inappropriate inflammation, tissue damage, and hepatic fibrosis. During
inflammation and injury, the functions of the ECM include providing structure,
facilitating adhesion, presenting cytokines to receptors, sequestering and storing
cytokines, and mechanical signal transduction.
The ECM plays an important structural role during inflammation and disease.
Under normal conditions, the ECM defines tissue boundaries (28). When the
tissue is injured, the super- and ultra- structure of the ECM is altered. As a
result, tissue boundaries are perturbed. Additionally, injury alters structural
components of the ECM (e.g. collagens I, IV, V, fibronectin, elastin) and thereby
affects the normal elasticity provided by the ECM (29).
Another role of the ECM during inflammation is regulation of the signaling of
cytokines and other APPs. The ECM acts as a chemokine reservoir.
Additionally, ECM binding of cytokines, including IL-2, TNFα, TGFβ, and

5

RANTES ((30-32), has been shown to regulate cell activation, adhesion, and
migration. For example, CCL2 is concentrated in the ECM at the site of injury.
Furthermore, glycosaminoglycan binding of chemokines can protect them from
proteolytic cleavage.
The ECM also acts as an adhesive substrate during inflammation. The ECM
directs inflammatory cells. For example, the ECM is critical in the process of
leukocyte adhesion and transmigration (33). Initial leukocyte capture and rolling
is mediated by selectins, arrest is medicated by integrins, and transmigration
involves adhesion molecules. The aforementioned chemokine gradients
mediated by the ECM also play an important role in directing immune cells.
During inflammation, the ECM also plays an important role in mechanical
signaling. During an acute inflammatory response, the ECM plays a pivotal role
by serving as a structural barrier. The ECM defines mechanical properties
permissive and/or instructive to inflammation. Indeed, studies have shown that
neutrophil transmigration is greater through vascular areas with lower ECM
concentration (34). The interaction between the ECM and cell infiltration is
bidirectional; as leukocytes integrate structural and biochemical signals from the
ECM, they in turn release matrix-degrading proteases (35) which alter the
extracellular composition and allow for easier cell migration.
ECM dysregulation during chronic inflammation can cause pathological tissue
remodeling. Over time, this remodeling can culminate in disease states such as
hepatic fibrosis (36, 37), pulmonary fibrosis (38-40), atherosclerosis (41, 42), and
cancer (43, 44). Dysregulated ECM synthesis and/or degradation can lead to
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altered matrix accumulation, which is the etiologic basis of these pathologies.
For example, robustly increased collagen Iα1 secretion by hepatic stellate cells
(HSCs) (45), increased crosslinking, and a decrease in enzymatic degradation
(46) all characterize hepatic fibrosis. These dynamic ECM changes can initiate
and perpetuate disease through multiple mechanisms, including altered tissue
biomechanics (i.e. tissue stiffness) (47, 48), increased integrin-mediated cell
adhesion (49) and activation of immune cells (50).

4. ECM remodeling and the “degradome”
As discussed previously, the ECM always has some level of dynamicity, even
under normal conditions, but can undergo more dramatic, rapid changes (i.e.
remodeling) during inflammation and disease. Changes in ECM components can
occur at all different levels, from protein synthesis to crosslinking or activation.
One important means of regulation of ECM components is through proteases
(e.g. MMPs). At different stages of liver injury, hepatic stellate cells express and
secrete different profiles of proteases and inhibitors (51), as do hepatocytes (52),
neutrophils (53), and macrophages (54). These proteases can release cytokines
from the matrix (55), but can also release a myriad of other peptides that may or
may not be bioactive. The roles of protease degradation products (i.e. the
‘degradome’) in various diseases are becoming increasingly understood. For
example, ECM degradation rate, the production rate of matrix degrading
enzymes (MDE), and the conversion of ECM into soluble ECM have been
demonstrated to strongly influence tumor growth and morphology (56).
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Understanding the role of the ECM degradome in disease is facilitated by
modern mass spectrometry methods that allow widespread characterization of
the degradome (i.e. peptidomics or ‘degradomics’) (57). Even if degradation
products do not play a critical role in disease mechanisms, they may be useful
surrogate biomarkers. These peptides are particularly attractive biomarker
candidates because they are often secreted into bodily fluids (58, 59). This
means that they could be detected using minimally invasive procedures (e.g.
blood draw).

5. Natural history of liver disease
No matter their etiology, liver diseases share a common natural history that
has been thoroughly documented. This natural history is comprised of a
spectrum of disease states including earlier stages of fatty accumulation and
inflammation, such as steatosis and steatohepatitis, and later stages of disease
such as fibrosis and cirrhosis (60, 61). Simple steatosis is the earliest stage of
liver disease and is characterized by micro- and macro-vesicular fat
accumulation. Steatosis may be reversible with lifestyle modifications or
progress to steatohepatitis. Steatohepatitis is characterized by persistent fat
accumulation, chronic inflammation, and necrosis (27). Fibrosis and cirrhosis,
the later stages of liver disease, are characterized by accumulation of fibrillar
collagens and regenerative nodules, respectively (61, 62).
Although there is a great need for and large amount of money spent on liver
disease treatment, therapeutic options are palliative at best. Currently there is no
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FDA-approved therapy to halt or reverse liver disease progression. A better
understanding of mechanisms of disease progression is needed, and new
therapeutic targets must be identified if a rational, targeted therapy is to be
developed.

6. Alcoholic liver disease
The liver is the primary site of alcohol metabolism and therefore the primary
target organ of alcohol toxicity. Indeed, after absorption from the small intestine,
milli-molar concentrations of ethanol flow through the portal circulation and to the
liver for degradation. Ethanol is at least 2-3 times more concentrated in portal
blood than in systemic circulation (63). Oxidative metabolism of ethanol in
hepatocytes by alcohol dehydrogenase (Adh) and cytochrome P450 2E1
(Cyp2e1) produces toxic intermediate metabolites (e.g., acetaldehyde). Ethanol
metabolism also causes a robust increase in the NADH/NAD+ ratio, which
creates a more reduced cellular environment. This reduced microenvironment
blocks the beta-oxidation of fatty acids and increases fatty acid esterification.
The accumulation of excess fatty acids, which are stored in lipid droplets,
characterizes steatosis, the earliest stage of alcoholic liver disease (ALD).
Most individuals who consume moderate amounts of alcohol develop
steatosis. Steatosis most often has no health consequences, and may even be
considered a protective mechanism, as it prevents plasma lipid levels from rising.
However, chronic alcohol consumption can cause progression to later stages of
ALD, including alcoholic steatohepatitis (ASH), fibrosis, and cirrhosis. Only a
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minority of even the heaviest drinkers will develop the most serious stages of
ALD. This suggests a 2-hit hypothesis in which progression to later stages of
liver disease requires multiple insults, or ‘hits’ (64, 65). The first ‘hit,’ such as
hepatic steatosis, sensitizes the liver to a second hit such as oxidative stress (65)
or inflammatory cytokine signaling (66), both of which are increased by ethanol
consumption.
Therefore, alcohol is one of the most commonly recognized causes of liver
disease. ALD affects more than 10 million Americans each year with medical
costs of more than $166 billion annually (67). There are no targeted therapies for
ALD, and current therapy focuses on achieving and maintaining abstinence.
Individuals with severe ALD are at risk of such acute alcoholic hepatitis (AH) or
cirrhosis (68). These sequelae of ALD have a poor prognosis and limited
therapeutic options. Without a successful liver transplant, patients typically die
from the effects of decompensation (e.g., hepatorenal syndrome) (69).
Additionally, cirrhosis increases the overall risk for hepatocellular carcinoma
(HCC) by roughly 20-fold, even in the case of compensated cirrhosis (70). Once
the HCC is symptomatic, it is usually unresectable (71). This cancer has a
dismal prognosis, with a median survival of less than 6 months and a five year
survival of almost nil (71). While the stages of ALD have been wellcharacterized, targeted therapies to prevent or reverse this process in humans
are still needed. Therefore, additional research is needed to improve
understanding of risk factors and mechanisms of disease progression and to
develop rational therapies to prevent or reverse ALD.
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Alcoholic hepatitis
AH is characterized by severe, acute hepatic inflammation, liver failure, and
jaundice (72). It is a sequelae of ALD that typically occurs after many years of
heavy alcohol consumption, and it has a high mortality rate (30-50% at 3 months,
(73)). Cause of death in AH patients is usually due to multiple organ failure
secondary to liver injury (74). AH patients are also at risk of systemic
inflammatory response syndrome (SIRS), which is associated with increased
mortality (75).
Therapeutic options for AH are limited. Liver transplantation for AH is
controversial and is currently not recommended, largely due to organ shortages
(76). Current pharmacologic treatment options for AH are limited to
corticosteroids or pentoxifylline, although the outcomes from the therapies are
poor. The benefits of anti-inflammatory pharmaceuticals only outweigh the risks
(e.g. infection) in patients with more severe AH (72). For this reason, assessing
AH severity and predicting patient outcome is important.
Predicting outcomes of AH patients is challenging. AH patients typically have
an AST/ALT greater than 2, but this measure is neither specific nor sensitive
(77). Alternatively, several clinical scoring systems have been developed. The
Maddrey discriminant function (DF) is based on serum bilirubin and PT/INR (78)
which are independent predictors of short‐term mortality in AH (79). The Model
for End‐Stage Liver Disease (MELD) score similarly utilizes serum bilirubin and
INR, but also considers creatinine. MELD has been shown to more accurately
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predict short‐term mortality in AH compared to DF (80). Other validated scores
include ABIC, Glasgow Alcoholic Hepatitis Score, the Child-Turcotte-Pugh score;
these have similar prognostic efficiency as MELD (81-83). These models are
highly limited in patients with coexisting kidney disease or chronic hemolysis not
related to the underlying liver disease (78). Furthermore, scores such as MELD
are more limited in predicting outcome of patients with more moderate AH (84).

7. Alcohol and the kidney
It is well established that ethanol is both directly toxic to the liver and can
sensitize the liver to a second-hit insult. Although the liver is the primary target
organ of ethanol toxicity, it is becoming increasingly understood that ethanol has
some level of toxicity in other organs, such as the brain, gut, lungs, and
pancreas. Chronic, heavy ethanol consumption causes kidney damage
secondary to hepatic cirrhosis, a phenomenon known as hepato-renal syndrome.
Moderate alcohol consumption, however, is currently not considered a risk factor
for chronic kidney disease. Furthermore, population based studies have shown
moderate alcohol consumption to be inversely associated with kidney injury (85).
However, the direct renal effects of chronic moderate EtOH consumption and
sensitization to secondary hits are unclear. Rodent studies have identified
several mechanisms of alcohol-induced kidney injury that parallel those observed
in the liver (86-88). These investigations have been driven by the hypothesis that
alcohol affects the kidneys similarly to the liver. It certainly is not surprising that
these parallel mechanisms have been confirmed, considering similarities
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between these two organs, such as the expression of CYP2E1 (86). However, it
is certainly possible that ethanol affects the kidneys by mechanisms that do not
parallel those in the liver. Therefore, further investigation into the effects of
ethanol on the kidneys is needed. Additionally, it is not known whether ethanol
exposure alters renal response to a second inflammatory ‘hit’, as has been
observed in the liver.

8. Statement of goals
It is well established that ethanol is toxic to the liver, and the natural history of
ALD is well characterized. However, there are no targeted therapies to halt or
reverse liver disease. Development of such therapies requires a better
understanding of mechanisms of disease progression as well as identification of
novel drug targets. Therefore, one goal of this dissertation is to shed new insight
into mechanisms of progression of ALD. In contrast to the liver, the effects of
ethanol on the kidneys are largely unknown. Therefore, another goal of this
dissertation is to elucidate mechanisms by which ethanol affects the kidneys.
Taken together, the goal of this dissertation is to examine new potential
mechanisms by which ethanol affects the liver and kidneys.

B. Aims and proposals

1. Characterization of alcohol-induced matrisome changes in liver
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As discussed in earlier sections, the role of the ECM in later stages of liver
disease (i.e., fibrosis) is well established. Previous studies from our group and
others have also demonstrated changes in the ECM in early liver disease, prior
to fibrogenesis (89-91). These studies suggest that these transitional ECM
changes may play an important role in the sensitization of the liver to insult.
While several matrix proteins have been implicated as players in liver injury and
inflammation (i.e., fibrin, fibronectin), this is only a small portion of the >1000
known ECM related proteins (92). Indeed, other ECM proteins likely also
contribute to hepatic injury. Identification of new ECM proteins that ethanol
exposure alters would help elucidate mechanisms of ALD progression. There
are likely changes in the hepatic ECM that have not yet been identified, due to
the insolubility of matrix proteins that makes them difficult to extract and analyze.
A limitation of previous studies focused on the role of the ECM in ALD is that they
generally studied changes in one ECM protein at a time and did not consider
structural changes that may accompany altered ECM protein turnover.
Additionally, the study of alterations to the hepatic ECM has primarily been
hypothesis-driven, which limits the discovery of novel potential players. This
study couples a serial extraction method that allows solubilization and
enrichment of tightly cross-linked proteins with LC-MS/MS analysis. This
approach allows analysis of global changes in the hepatic ECM.

2. Novel biomarkers in alcoholic hepatitis: analysis of the plasma
peptidome/degradome
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AH is characterized by acute liver inflammation and liver failure. It was
hypothesized that this inflammation would involve transitional remodeling of the
hepatic ECM, and that this remodeling would cause the accumulation of ECM
degradation products (peptides) in the blood. Therefore, the plasma peptidome
in AH patients was analyzed. This builds upon the work in Aim 1 of this
dissertation, which will demonstrated that the hepatic ECM undergoes significant
remodeling during inflammatory liver injury (93). This remodeling involves
protease cleavage of ECM proteins, which yields ECM peptide fragments (94).
During remodeling, peptide fragments of the degraded ECM have been shown to
increase in biologic fluids (e.g. plasma) (58, 59). Peptidomic analysis of the
degraded ECM (i.e., ‘degradome) has been identified as a useful
diagnostic/prognostic tool in other diseases of ECM remodeling, such as chronic
obstructive pulmonary disease (COPD) (58) and metastatic cancers (59).
Current methods of predicting AH outcome (i.e. clinical scores, e.g. MELD) are
limited in their abilities to predict at-risk patients with moderate disease (84).
Therefore, the purpose of this study was to test the hypothesis that the severe
inflammatory liver injury caused by AH would yield a unique degradome profile in
patient plasma. This was done using a peptidomic workflow analysis of plasma
from healthy participants or AH patients. This is expected to reveal unique
patterns of ECM peptides or ‘features’ across different severity groups of AH
patients This analysis lays the groundwork for further studies investigating the
plasma ECM degradome as potential surrogate or mechanistic biomarkers for
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AH patient outcome. The characterization of the AH plasma degradome also
supports future mechanistic studies on the role of ECM remodeling in AH.

3. Pathways affected by alcohol in the kidney
The effects of ethanol consumption on the kidneys are poorly understood in
contrast to the liver. Some human studies have reported benefits of chronic
moderate EtOH consumption for preservation of renal function (85, 95).
However, the small number of rodent studies on the effects of ethanol on the
kidneys have reported that chronic ethanol consumption upregulates Cyp2e1
(88), causes neutrophil infiltration (88), and increases acetylation of mitochondrial
proteins (86) in the kidney. However, these previous studies have been limited
by the hypothesis that ethanol affects the kidneys by mechanisms parallel to
those in the liver. It was hypothesized that there are additional mechanisms by
which ethanol affects the kidneys that do not necessarily parallel mechanisms in
the liver. Aim 3 of this dissertation tests this hypothesis using a discovery-based
proteomic and transcriptomic approach to discover novel players and pathways
affected by ethanol and LPS in the renal cortex.

Overall aim of this dissertation.
The overall aim of this dissertation is to provide new insight into mechanisms
of alcohol-induced organ injury. To this end, a novel method of analyzing the
hepatic matrisome will be used to determine the effects of chronic, moderate
ethanol consumption and acute inflammation on the hepatic matrisome in mice
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(Aim 1). Next, ECM degradome (peptidome) in AH patient plasma will be
analyzed (Aim 2), allowing for future investigation into the use of plasma ECM
peptides as surrogate or mechanistic biomarkers. Finally, a discovery based
‘omics approach will be used to elucidate the effects of ethanol consumption on
the kidneys (Aim 3). Taken together, this work will shed new mechanistic insight
into alcohol-induced organ injury.
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CHAPTER II

EXPERIMENTAL PROCEDURES

A. Animals and exposures
Animal experiments were carried out by the Arteel laboratory. Mice were
housed in a pathogen-free barrier facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care, and procedures were
approved by the University of Louisville’s Institutional Animal Care and Use
Committee.

1. Animal sacrifice, tissue collection and storage
At time of sacrifice, animals were anesthetized with ketamine/xylazine
(100/15 mg/kg, intraperitoneally (i.p.)). Blood was collected from the vena cava
just before sacrifice. Citrated plasma was stored at -80 ⁰C for further analysis.
Portions of liver and renal cortex tissue were snap-frozen in liquid nitrogen, fixed
in 10% neutral buffered formalin for subsequent sectioning and mounting on
microscope slides, or frozen-fixed in Tissue Tek OCT-Compound (Sakura
Finetek, Torrance, CA).

2. Carbon tetrachloride model of hepatic fibrosis
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Male (4-6 weeks old) C57BL6/J mice were purchased from Jackson
Laboratory (Bar Harbor, ME). Mice were injected with CCl4 (1 mL/kg i.p.; diluted
1:4 in olive oil; Sigma-Aldrich, St. Louis, MO) or vehicle
twice a week for 4 weeks (96).

3. Chronic model of alcohol exposure
Male (8 weeks old) C57BL6/J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Mice were given ethanol-containing Lieber-DeCarli
diet (Dyets, Inc.) ad libitum or pair-fed isocaloric/isovolumetric maltose-dextrin
control diet (97). During the exposure period, animals were housed in pairs in
shoebox cages in a room held at 75 °F. Diet was provided in vacuum tubes and
replaced between 4 and 5 pm daily. Both ethanol-fed animals and their pair-fed
counterparts received control diet for the first two days of liquid diet feeding to
allow acclimation to the liquid diet feeders. After 2 days of acclimation, ethanol
concentrations increased incrementally over the course of three weeks before
reaching the highest ethanol concentration, 6% (vol/vol) for the final three weeks
of exposure. Ethanol concentrations in the ethanol-containing diets were as
follows: 0% for two days of acclimation, 1% for two days, 2% for two days, 4% for
one week, 5% for one week, and 6% for three weeks. Ethanol-containing diet
was provided ad libitum for the entire course of the study. Because of the
relatively high caloric content of ethanol, pair-fed control animals received an isocaloric control diet; the calories in the iso-caloric diet were matched by adding a
calorie-equivalent of maltose-dextrin. To account for the reduced food
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consumption of ethanol-fed mice, pair-fed mice were given the volume of diet
consumed by their ethanol-fed counterparts the night before. At the conclusion of
the feeding period, the two diet groups were further separated into additional
groups that received either LPS (Escherichia coli; 10 mg/kg i.p. Sigma, St. Louis,
MO) or vehicle (saline). Animals were euthanized 4 or 24 h after LPS (or vehicle)
injection (97). 6 control mice, 5 ethanol mice, 6 24-h LPS mice, and 4
ethanol+24h LPS mice were used for the hepatic matrisome analysis. 3 control
mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice were used for
the renal cortex proteomic and transcriptomic analyses. The same mice were
used for the renal cortex proteomics and transcriptomics, except for 1 4h LPS
mouse and 1 ethanol+4h LPS mouse that were different.

4. Chronic+binge model of alcohol exposure
Male (10 weeks old) C57BL6/J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Mice were exposed to ethanol as described by
Bertola et al. (98). During the exposure period, animals were housed in pairs in
shoebox cages in a room held at 75 °F. Diet was provided in vacuum tubes and
replaced between 4:00 and 5:00 PM daily. Animals were acclimatized to control
(0% EtOH) Lieber-DeCarli liquid diet (Dyets, Inc., Bethlehem, PA) for 5 days.
Mice were then split into two groups fed ethanol-containing (5% v/v) or iso-caloric
control liquid diet for 10 days. To account for the reduced food consumption of
ethanol-fed mice, pair-fed mice were given the volume of diet consumed by their
ethanol-fed counterparts the night before. On day 11, mice received ethanol (5
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g/kg) or iso-caloric maltose dextran binge via oral gavage. Mice were sacrificed
9 hours post-gavage. Tissues were collected as described in section A1.

B. Proteomics
1.

3-step ECM extraction

Sequential extraction of the hepatic ECM was performed as described by
de Castro Bras et al. for heart tissue (99), with minor modifications for liver.
Sample preparation and wash. Snap frozen liver tissue (75-100 mg) was
immediately added to ice-cold phosphate-buffered saline (pH 7.4) wash buffer
containing commercially available protease and phosphatase inhibitors (Sigma
Aldrich) and 25 mM EDTA to inhibit proteinase and metalloproteinase activity,
respectively. While immersed in wash buffer, liver tissue was diced into small
fragments using a scalpel. The diced sample was washed 5 times to remove
contaminants. Between washes, samples were pelleted by centrifugation
(12,000×g, 5 min), and wash buffer was decanted.
NaCl extraction. Diced samples were incubated in 10 volumes of 0.5 M
NaCl buffer, containing 10 mM Tris HCl (pH 7.5), proteinase/phosphatase
inhibitors, and 25 mM EDTA. The samples were mildly mixed on a plate shaker
(800 rpm) overnight at room temperature. The following day, the remaining
tissue pieces were pelleted by centrifugation (10,000×g for 10 min). The pellet
was used for the SDS extraction (see below). The supernatant was collected
and desalted using ZebaSpin columns (Pierce) according to manufacturer’s
instructions. To precipitate proteins, desalted supernatant was incubated with 5x
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supernatant volume of 100% acetone overnight at -20 °C, centrifuged (16,000×g,
45 min), and dried in a rotary evaporator. Proteins were resuspended in
deglycosylation buffer. SDS extraction. The pellet from the NaCl extraction was
subsequently incubated in 10 volumes (based on original weight) of 1% SDS
solution, containing proteinase/phosphatase inhibitors and 25 mM EDTA. The
samples were mildly mixed on a plate shaker (800 rpm) overnight at room
temperature. The following day, the remaining tissue pieces were pelleted by
centrifugation at 10,000×g for 10 min. The pellet was used for the GnHCl
extraction (see below). The supernatant was collected and desalted using
ZebaSpin columns (Pierce) according to manufacturer’s instructions. To
precipitate proteins, desalted supernatant was incubated with 5× supernatant
volume of 100% acetone overnight at -20 °C, centrifuged (16,000×g, 45 min),
and dried in a rotary evaporator. Proteins were resuspended in deglycosylation
buffer. Guanidine HCl extraction. The pellet from the SDS extraction was
incubated with 5 volumes (based on original weight) of a denaturing guanidine
buffer containing 4 M guanidine HCl (pH 5.8), 50 mM sodium acetate, 25 mM
EDTA, and proteinase/phosphatase inhibitors. The samples were vigorously
mixed on a plate shaker at 1200 rpm for 48 hours at room temperature; vigorous
shaking is necessary at this step to aid in the mechanical disruption of ECM
components. The remaining insoluble components were pelleted by
centrifugation at 10,000×g for 10 minutes. This insoluble pellet was retained and
solubilized as described below. To precipitate proteins, the supernatant was
mixed with 6× supernatant volume of 100% ice cold ethanol overnight at 20 °C,
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centrifuged (16,000×g, 45 min), and washed with 90% ethanol. Pellets were
dried in a rotary evaporator and resuspended in deglycosylation buffer.
Deglycosylation and solubilization. The supernatants from each extraction were
dried in a rotary evaporator and resuspended in deglycosylation buffer containing
150 mM NaCl, 50 mM sodium acetate, 10 mM EDTA, and
proteinase/phosphatase inhibitors. Resuspended samples were desalted using
ZebaSpin columns (Pierce) according to manufacturer’s instructions. The
desalted extracts were then mixed with 5 volumes of 100% acetone and stored at
-20°C overnight to precipitate proteins. The precipitated proteins were pelleted
by centrifugation at 16,000×g for 45 minutes. Acetone was evaporated by
vacuum drying in a rotary evaporator for 1 hour. Dried protein pellets were
resuspended in 500 µL deglycosylation buffer containing 150 mM NaCl, 50 mM
sodium acetate, pH 6.8, 10 mM EDTA, and proteinase/phosphatase inhibitors
that contained chondroitinase ABC (P. vulgaris; 0.025 U/sample), endo-betagalactosidase (B. fragilis; 0.01 U/sample) and heparitinase II (F. heparinum;
0.025 U/sample). Samples were incubated overnight at 37°C. 20 uL DMSO was
added to the insoluble fraction (pellet from guanidine HCl extraction) to aide in
solubilization. Protein concentrations were estimated by absorbance at 280 nm
using bovine serum albumin (BSA) in deglycosylation buffer for reference
standards.

2.

Total protein extraction
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This extraction was carried out in the Merchant laboratory. Proteins were
extracted from snap frozen renal cortex tissue using lysis buffer (1:1 w/v)
containing 10% glycerol, 50 mM HEPES, 100 mM KCl, 2 mM EDTA, 0.1%
Nonidet p-40 (NP-40), 2 mM DTT, 10 mM NaF, 0.25 mM NaVO3, and 1x Halt
Protease and Phosphatase Inhibitor Cocktail (ThermoFisher). Samples were
placed in a sonication bath for 5 minutes, incubated on ice for 1 hour, and
centrifuged at 12,000×g for 30 minutes. Extract was removed from insoluble
matter. Protein concentrations were assayed using standard Bradford assay with
BSA for reference standards.

3. Sample cleanup and preparation for liquid chromatography and
mass spectrometry
Liver ECM extracts in deglycosylation buffer were pooled by experimental
group and subsequently analyzed by the University of Louisville Proteomics
Biomarkers Discovery Core (PBDC). At the PBDC, samples in deglycosylation
buffer were thawed to room temperature and clarified by centrifugation at
5,000xg for 5 min at 4°C. 50 µL (25 µg) of each sample were reduced by adding
5.55 µL of 1 M DTT and incubating at 60°C for 30 min. 144.45 µL of 8 M urea in
0.1 M Tris-HCl, pH 8.5, was added to each sample. Each reduced and diluted
sample was digested with a modified Filter-Aided Sample Preparation (FASP)
method developed by Jacek R. Wisniewski, et al. (100). Recovered material was
dried in a rotary evaporator and redissolved in 200 μL of 2% (v/v) acetonitrile
(ACN)/0.4% formic acid (FA). The samples were then trap-cleaned with a C18
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PROTOTM 300Å Ultra MicroSpin Column (The Nest Group, Southborough, MA).
The sample eluates were stored at -80°C for 30 min, dried in a rotary evaporator,
and stored at -80°C. Before liquid chromatography, dried samples were warmed
to room temperature and dissolved in 2% (v/v) ACN/0.1% FA to a final
concentration of 0.25 μg/μL. 16 μL (4 μg) of sample was injected into the
Orbitrap Elite.
Renal cortical proteins (100µg) were digested using a FASP protocol (100)
to remove NP-40 detergent used for sample preparation. Proteomic analysis of
tissue lysates was conducted as previously described (101) with the following
modifications. Proteins were digested with Lys-c (Promega #V167A) and trypsin
(Promega #V5111), each at a 1:100 w/w enzyme:protein ratio. Peptides were
desalted using HLB extraction (Waters Oasis HLB 1cc, WAT094225) (102). 50
µg peptide were dried and resuspended in 100µL 100mM triethylammonium
bicarbonate (TEABC). Peptide concentrations were measured using an A205
nm assay with an external peptide standard curve.

4. TMT labeling
Tandem mass tag (TMT) 10-plex labeling (Thermo 90111) of renal cortical
digests was carried out according to manufacturer’s instructions. 50 µg peptide
in 100 µL 100 mM TEABC were added to each label tube. Labeled samples
were admixed, dried, and resuspended in 800 µL 0.1% v/v FA. Peptide
concentrations were measured using an A205 nm assay with an external peptide
standard curve. 200 µg peptide were fractionated by strong cation exchange
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using 30-300 µg capacity SCX MacroSpin Columns (SMM HIL-SCX.25, Nest
Group, Inc. Southborough, MA, USA) according to manufacturer’s instructions.
Sample cleanup was performed using C18 PROTO, 300 Å Ultra Microspin
Columns (Nest Group, Inc., Southborough, MA, USA).

5. Liquid chromatography and tandem mass spectrometry
At the PBDC, liver digest samples were separated on a Dionex Acclaim
PepMap 100 75 μm x 2 cm nanoViper (C18, 3 µm, 100 Å) trap and Dionex
Acclaim PepMap RSLC 50 μM x 15 cm nanoViper (C18, 2 µm, 100 Å) separating
columns. An EASY n-LC (Thermo, Waltham, MA) UHPLC system was used with
buffer A = 2% (v/v) ACN/ 0.1% (v/v) FA and buffer B = 80% (v/v) ACN / 0.1%
(v/v) FA as mobile phases. Following injection of the sample onto the trap,
separation was accomplished with a 140 min linear gradient from 0% B to 50%
B, followed by a 30 min linear gradient from 50% B to 95% B, and lastly a 10 min
wash with 95% B. A 40 mm stainless steel emitter (Thermo, Waltham, MA; P/N
ES542) was coupled to the outlet of the separating column. A Nanospray Flex
source (Thermo, Waltham, MA) was used to position the end of the emitter near
the ion transfer capillary of the mass spectrometer. The ion transfer capillary
temperature of the mass spectrometer was set at 225°C, and the spray voltage
was set at 1.6 kV.
An Orbitrap Elite – ETD mass spectrometer (Thermo) was used to collect
data from the LC eluate. An Nth Order Double Play with ETD Decision Tree
method was created in Xcalibur v2.2. Scan event one of the method obtained an
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FTMS MS1 scan for the range 300-2000 m/z. Scan event two obtained ITMS
MS2 scans on up to ten peaks that had a minimum signal threshold of 10,000
counts from scan event one. A decision tree was used to determine whether
collision induced dissociation (CID) or electron transfer dissociation (ETD)
activation was used. An ETD scan was triggered if any of the following held: an
ion had charge state 3 and m/z less than 650, an ion had charge state 4 and m/z
less than 900, an ion had charge state 5 and m/z less than 950, or an ion had
charge state greater than 5; a CID scan was triggered in all other cases. The
lock mass option was enabled (0% lock mass abundance) using the 371.101236
m/z polysiloxane peak as an internal calibrant.
TMT-labeled renal cortex tryptic digest SCX fractions underwent 1D-LCMS/MS analysis using a Proxeon EASY-nLC 1000 UHPLC and nanoelectrospray
ionization into an Orbitrap Elite mass spectrometer (Thermo) using a transfer
capillary temperature set of 225°C and the spray voltage of 1.6kV. An Nth Order
Double Play method was used with scan event one. An FTMS MS1 scan
(normal mass range; 60,000 resolution; full scan type) for the 400-2000 m/z
range was used, with charge state screening and monoisotopic precursor
selection enabled. Charge state rejection was enabled for unassigned charge
states and +1 charge states. The lock mass option was enabled (0% lock mass
abundance) using the 445.120028 m/z polysiloxane peak as an internal calibrant.
Scan event two obtained HCD FTMS MS2 scans (normal mass range; 60,000
resolution; centroid data type) on up to twelve peaks that had a minimum signal
threshold of 5,000 counts from scan event one. Dynamic exclusion was enabled
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with a repeat count of one, a repeat duration of 60 seconds, an exclusion list size
of 500, an exclusion duration of 60 seconds, and an exclusion mass width of
±0.001% relative to reference mass (93).

6. Informatics
The hepatic ECM mass spectrometry data were analyzed at the University of
Louisville PBDC using Proteome Discoverer v1.4.0.288. The database used in
Mascot v2.4 and SequestHT searches was the 6/2/2015 version of the UniprotKB
Mus musculus reference proteome canonical and isoform sequences. +57 on C
(Carbamidomethylation) was selected as a fixed modification, and +1 on N (Asn>Asp) and +16 on MP (Oxidation) were selected as variable modifications. A
maximum of two missed cleavages were allowed. A Target Decoy PSM
Validator node was included in the Proteome Discoverer workflow in order to
estimate the false discovery rate (FDR).
The Proteome Discoverer analysis workflow allows for extraction of MS2
scan data from the Xcalibur RAW file, separate searches of CID and ETD MS2
scans in Mascot and Sequest, and collection of the results into a single file (.msf
extension). The resulting .msf files from Proteome Discoverer were loaded into
Scaffold Q+S v4.3.2. Scaffold was used to calculate the FDR using the Peptide
and Protein Prophet algorithms. Protein identification probability of the
sequences was set to >95% on the software. The results were annotated with
mouse GO information from the Gene Ontology Annotations Database.
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Renal cortex mass spectrometry data were analyzed at the University of
Louisville PBDC using Proteome Discoverer v1.4.0.288 and Scaffold Q+S v4.3.2
with the 6/2/2014 version of the UniprotKB Mus musculus reference proteome
canonical and isoform sequences. A Target Decoy PSM Validator node was
used to control the FDR and a Reporter Ions Quantifier node was included for
quantification of the TMT reporter ions considering TMT purity correction factors
obtained from the manufacturer. Intensity based normalization of reporter ions
was achieved using the mean calculation type, modeled on unique peptides, and
using an average protein reference. Scaffold was used to calculate the FDR
using the Peptide and Protein Prophet algorithms.

C. Immunoblots
1. Dot blot
Liver samples from the chronic EtOH model were homogenized in
radioimmunoprecipitation assay (RIPA) buffer containing protease and
phosphatase inhibitor cocktails (Sigma; St. Louis, MO). 10 μg protein in 100 μl
RIPA buffer were loaded onto nitrocellulose membranes (GE Healthcare) using a
vacuum-assisted microfiltration system (Bio-Dot; Bio-Rad, Hercules, CA). The
membrane was blocked for one hour with 5% non-fat milk in TBST. Primary
antibodies against collagen type I α1 (Meridian T40777R) and GAPDH (Santa
Cruz SC-25778) were used. Densitometric analysis was performed using UNSCAN-IT gel (Silk Scientific Inc., Orem, Utah) software.
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2. Western blot
Renal cortex immunoblot was carried out as described previously (103) using
a primary antibody against Cat (Cell Signaling D5N7V). Densitometry of
exposed film was analyzed using the ImageJ software (ImageJ, NIH,
http://rsb.info.nih.gov/ij/).

D. Transcriptomics
1. RNA isolation
Snap frozen renal cortex sections were stored at -80° C and then incubated in
RNAlater-ICE (Life Technologies, Carlsbad, CA) at -20° C for 72 hours prior to
RNA extraction. RNA was isolated using the mirVana kit (Life Technologies,
Carlsbad, CA) according to manufacturer’s instructions for total RNA isolation.
RNA quality was evaluated by Nanodrop ND-1000 (Thermo Fisher Scientific,
Grand Island, NY) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA)
analysis. Ribosomal depletion was carried out at the University of Louisville
Center for Genetics and Molecular Medicine (CGeMM) prior to RNA seq
analysis.

2. RNA sequencing
RNA libraries were prepared using the TruSe Stranded Total RNA LT
sample preparation Kit- Set A with Ribo-Zero Gold. Sequencing was performed
on the University of Louisville CGeMM’s Illumina NextSeq 500/550 75 cycle High
Output Kit v2.
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3. RNASeq data analysis
RNA Seq data were analyzed at the University of Louisville CGeMM using
the Tuxedo suite data analysis pipeline. Differentially expressed transcripts were
identified by filtering by analysis of variance (ANOVA) p-value cutoff (p<0.05), a
more stringent Benjamini-Hochberg (BH) q-value cutoff (q<0.01) and FC cutoffs
of 1.2 (to explore pathways analysis) and 2 (to address larger changes in RNA
expression).

E. Histology and Immunohistochemistry
1. Histology
In the Arteel laboratory, paraffin-embedded, formalin fixed liver sections from
the CCl4 study were stained with Sirius Red/Fast Green to visualize fibrosis (96).
Paraffin-embedded, formalin fixed renal cortex sections from the chronic
EtOH study were periodic acid-Schiff (PAS) stained (103) in collaboration with
Dr. Michelle Barati. Blinded histology was reviewed by a fellowship-trained,
board certified pathologist. It was determined that there were no differences
between groups, and so staining was not quantified.

2. Immunohistochemistry
In collaboration with Dr. Michelle Barati, immunohistochemistry (IHC) was
carried out on renal cortex sections using a primary antibody against
myeloperoxidase (Mpo, Abcam ab9535) and catalase (Cat, Cell Signaling
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D5N7V) (103). Mpo staining was quantified as average number of Mpo positive
cells per visual field (40x) with an average number of 33 ± 4 visual fields per
kidney section. An n of 3 samples in each experimental group were analyzed.
Differences between groups were determined by 2-way ANOVA and post-hoc ttests.

F. Clinical chemistry
1. Blood urea nitrogen analysis
Blood urea nitrogen (BUN) in mouse plasma from the chronic and
chronic+binge EtOH studies was measured using the Urea Assay Kit (Abnova
KA1652) according to manufacturer’s instructions.

G. Clinical study
1. Study participants
Plasma samples and clinical data from the following study were provided
through collaboration with Dr. Craig McClain and Dr. Vatsalya Vatsalya. This
study was approved by the Institutional Review Boards at all the participating
centers. This study was a part of a large national multisite clinical trial indexed at
clinicaltrials.gov: NCT01922895 and NCT01809132. All moderate and severe AH
patients were enrolled at the University of Louisville, the University of
Massachusetts Medical School, the University of Texas-Southwestern and the
Cleveland Clinic. All AUD (“mild”) patients were enrolled at NIAAA, NIH. All
healthy volunteers were recruited at the Louisville site. All AH patients were
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diagnosed using clinical and laboratory criteria described by the NIAAA
consortium on AH (104). Individuals with or without liver injury met the criteria for
AUD based on DSM 4 XR or DSM 5 manual. All healthy participants were free of
any clinically diagnosed disease (liver or organ systems) that might contribute to
altered laboratory values in comparison analyses. All patient specimens and
data were analyzed at the University of Louisville.

2. Inclusion criteria
Eligible participants were 21 years old or older. The following individuals
were ineligible for participation 1) those unwilling or unable to provide informed
consent; and/or 2) those who had significant comorbid conditions (heart, kidney,
lung, neurological or psychiatric illnesses, sepsis) and/or active drug abuse;
and/or 3) pregnant/lactating women; and/or 4) prisoners or other vulnerable
persons.

3. Study paradigm
112 adult male and female individuals participated in this NIH-funded study.
This investigation was a single time point assessment of patients between the
study cohorts. The cohorts included healthy participants (n=7), patients with
AUDs (“mild” , MELD<12; n=45), patients with “moderate” AH (MELD=12-19;
n=23), patients with “severe” AH (>19; n=37). The mild/AUD group was both
analyzed as whole and also as sub-groups without liver injury (“mild-A”, serum
alanine aminotransferase (ALT)<40, n=14) and with liver injury (“mild-B”,
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ALT≥40, n=31). Informed consent was obtained from all study participants
before collection of data and bodily samples. Clinical data, relevant medical
history, measures of severity of ALD, and drinking history [using the Alcohol Use
Disorders Identification Test (AUDIT) (105) (only in moderate and severe AH
patients) and lifetime drinking history (LTDH) in all AH and AUD patients (106)
were collected. The study was designed to analyze plasma peptides for
comparison between healthy volunteers, AUD patients (with or without liver
injury), patients with moderate AH, and patients with severe AH for potential
associations between parameters. All data collected from the enrolled study
participants were de-identified, coded, and analyzed.

4. Collection of clinical data
Clinical data include participant demographics [age, sex, body mass index
(BMI)], drinking history (AUDIT and LTDH), medical assessments at admission
(after obtaining consent, specific for the study to exclude any condition that might
affect liver tests), and medical history. Confirmatory tests for AH (laboratory and
imaging), and markers of liver disease severity [Child-Turcotte-Pugh (CTP),
MELD, Maddrey DF] were also obtained. Laboratory tests included a
comprehensive metabolic profile with indices of liver injury [including serum ALT),
aspartate aminotransferase (AST), total bilirubin (Tbili)] and coagulation.

5. Plasma collection
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Blood samples were collected from each study participant following consent.
Blood was collected in lavender- top Vacutainer tubes containing K3 EDTA.
Blood was separated by centrifugation, and plasma was apportioned into 1 mL
aliquots and stored at -80 °C until use. Freeze-thaw cycles were avoided to
maintain the integrity of the plasma.

H. Peptidomics
1. Peptidomic workflow optimization
During workflow optimization, peptides were purified by ACN precipitation.
100 µL plasma were acidified with 100 µL 10% v/v acetic acid. To precipitate
proteins and impurities, 600 µL 99.9% v/v ACN / 0.1% v/v trifluoroacetic acid was
added to each sample, on ice. Samples were vortexed for 30 seconds, and
precipitate was pelleted by centrifugation at 15,000 × g for 15 minutes at 4 °C.
Pellets were discarded. Supernatants were collected and centrifuged again as
before. Again, supernatants were collected, and pellets were discarded.
Samples underwent cleanup and LC-MS/MS analysis as described in
sections 3 and 4. The LC-MS/MS analysis determined that the purity of the
peptide samples was unsatisfactory for the relative quantification of peptide
abundance. For this reason, the ACN precipitation method was abandoned. The
trichloroacetic acid (TCA) precipitation approach developed by Parker et al,
described below, was adopted (107). Parker et al. demonstrated that TCA
precipitation yields more peptides compared to ACN precipitation, acetone
precipitation, and size-exclusion 10 kDa MWCO filtration.
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2. Plasma peptide purification
To avoid systematic bias, the plasma samples were handled as four sample
flights (flight 1-4), each composed of balanced proportions of all groups with the
sample order interwoven into a randomized fashion. Total plasma peptides were
purified by TCA precipitation based on Parker et al. (107). 100 µL PBS with K3
EDTA was added to 100 µL plasma. Samples were mixed and incubated at RT
for 5 minutes. Samples were placed on ice, and 200 µL 20% w/v TCA (prechilled
to 4 °C) were mixed into each sample. Samples were allowed to incubate for 1
hour on ice. Precipitate was pelleted by centrifugation at 16,000 × g for 10
minutes at 4 °C; pellets were discarded. Supernatant collection, centrifugation
and discarding of pellets was repeated twice to ensure efficient removal of high
molecular weight proteins.

3. Peptide sample cleanup and preparation for liquid chromatography
and mass spectrometry
275 µL of each sample was desalted and concentrated using solid phase
extraction (Waters Oasis HLB µElution 30 µm plate, part no. 186001828BA) as
previously described by Keshishian, et al. (102). Solid phase extraction eluates
were dried in a rotary evaporator, and dried peptides were resuspended in 25 µL
2% v/v ACN/ 0.1% v/v FA. Peptide concentrations were measured by
absorbance at 250 nm.
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4. Liquid chromatography and tandem mass spectrometry
A high mass accuracy approach was used for relative quantification of plasma
peptides isolated from AH patients, AUD patients with and without liver injury,
and healthy volunteers plasma samples using a label-free approach. Peptides
were prepared to a concentration of 0.1 µg/µL in 2% v/v ACN/ 0.1% v/v FA. A
commercial mixture of 11 synthetic peptides (iRT1-11, Biognosis USA, Beverly,
MA) eluting across the chromatographic retention time spectrum were spiked into
each sample following peptidome resuspension. Peptides were separated by
reverse phase chromatography on a Proxeon EASY-nLC 1000 UHPLC system.
2 µL (0.2 µg) of each peptide sample was injected in random order. The trap
column used was a 75µm i.d. x 2cm Acclaim PepMapTM 100 nanoViper
cartridge packed with C18, 3µm, 100Å material(Thermo); the separating column
used was a 75µm i.d. x 50cm Acclaim PepMap RSLC nanoViper column packed
with C18, 2µm, 100Å material (Thermo). The separation was performed with a
gradient of solvent A = 2% v/v ACN / 0.1% v/v FA and solvent B = 80% v/v ACN /
0.1% v/v FA. After loading the sample onto the trap for 6min at 2µL/min in
solvent A, the sample was eluted and separated at 250nL/min with a gradient
from 0% to 55% solvent B over 165min. Following the gradient, the columns
were washed at 300nL/min for 10min with 95% solvent B and then returned to
initial conditions.
Liquid chromatography eluate was analyzed with an Orbitrap Elite mass
spectrometer with nanoelectrospray ionization. An Nth Order Double Play was
created in Xcalibur v2.2. Scan event one of the method obtained an FTMS MS1
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scan (normal mass range; 240,000 resolution, full scan type, positive polarity,
profile data type) for the range 300-2000m/z. Scan event two obtained ITMS
MS2 scans (normal mass range, rapid scan rate, centroid data type) on up to
twenty peaks that had a minimum signal threshold of 5,000 counts from scan
event one. The lock mass option was enabled (0% lock mass abundance) using
the 371.101236m/z polysiloxane peak as an internal calibrant.

I. Informatics
1. Liver ECM proteomic data analysis
Hepatic protein enrichment was quantified using total ion current (TIC).
Within Scaffold, proteins were filtered for extracellular GO annotation. The NaCl,
SDS, GnHCl, and pellet fractions contained 89, 63, 84, and 46 extracellular
proteins, respectively. Additional analysis was only performed on these proteins
that were classified as extracellular by GO annotation. The extracellular proteins
were further categorized into four classes based on their role in the extracellular
space as determined by a comprehensive literature search. These four ECM
groups include class 1) glycoproteins and proteoglycans, class 2) other ECMassociated proteins, class 3) proteases and protease inhibitors, and class 4)
collagens. If no record could be found supporting the hypothesis that a protein
was associated with the ECM, the protein was placed into (5), other proteins.

2. Renal cortex proteomic data analysis
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Renal cortex data were filtered by BH corrected ANOVA p-value <0.05 and
fold change (FC) ≥ 1.2. Ingenuity Pathways Analysis (IPA) was used to identify
pathways changed by EtOH, LPS, and/or the combination. The PANTHER web
application was used to identify statistically overrepresented GO cellular
compartments in groups of proteins that were significantly regulated by EtOH,
LPS, and EtOH + LPS compared to control. The statistical overrepresentation
test was carried out for (A) GO cellular component complete, (B) within each
cellular compartment, and (C) for GO biological process complete and with
Bonferroni correction using default settings.

3. Multivariate analysis of renal cortex proteomic and transcriptomic
data sets
Hierarchical clustering of the top-20 GO biological process terms for the
proteomic and the transcriptomic data sets were conducted using the
Heatmapper web application (www.heatmapper.ca). Data were clustered using
an average linkage method and a Spearman Rank Correlation distance
measurement method.

4. AH plasma peptidome data analysis
Peptide spectra collected in a data dependent fashion were interpreted using
a de novo spectrum assignment approach that enabled shotgun analysis of
peptide post-translational modification. The AUC for high resolution extracted ion
chromatograms were used as a label-free relative quantification of the peptide
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abundances. Quantitative and qualitative feature data were extracted and
analyzed using PEAKS Studio (v8.5). Data were normalized to TIC. The
following data analysis was done in collaboration with Dr. Shesh Rai and Dr.
Sudhir Srivastava. There were 1730 peptides initially. In each group, a peptide
was discarded if all observations were missing. Therefore, peptides having at
least one observation across all samples in each group were retained for further
analysis. After this filtering, 1273 peptides remained. Data were normalized by
taking log base 2 of raw data followed by quantile normalization using
“normalize.quantiles” function (108) available in R package “preprocessors”.
Missing values were imputed using the “SVD” (109) method under the
assumption of MAR. The R package “imputeLCMD” was used for imputing the
missing values. We used the imputed data for further analysis (see section J2).

J. Statistics
1. Statistical analysis of liver ECM proteomic data
Heat maps were compiled in the Arteel laboratory by Dr. Shanice Hudson in
the open-source statistical programming language R (R Development Core
Team. R: A language and environment for statistical computing.Vienna, Austria:
R Foundation for Statistical Computing, 2008.). ECM proteome output as Log2
FC of control was analyzed with the heatmap.2 function of the gplots package,
using the methods described by Key et al. (110) Pearson’s correlation coefficient
was used to measure distance, and the Ward method (ward.D) was the
agglomeration method for row and column clustering. In addition, protein
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distribution patterns across the four treatment groups were clustered using
hierarchical clustering (function hclust within R package cluster) (Cluster analysis
basics and extensions: R package version [computer program]. Version 1.15.3
2014). Patterns were clustered separately for each fraction, and the optimal
number of clusters was determined using a combination of statistical measures
(R package clValid) (Brock G, Pihur V, Datta S, Datta S. clValid: An R package
for cluster validation. Journal of Statistical Software 2008;25:1-22.) and biological
interpretability. Since interest was in the pattern of abundance across the
treatment groups, abundance values for each protein were standardized to mean
zero and standard deviation one for each protein prior to clustering.

2. Statistical analysis of alcoholic hepatitis plasma peptidomic data
Statistical analyses of the peptidomic data were carried out in collaboration
with Dr. Shesh Rai and Dr. Sudhir Srivastava. A non-discriminant data reduction
method termed principal components analysis (PCA) was used to evaluate the
data at the patient level and determine the ability of the data to ‘self-sort’ into
discrete groups. To evaluate the data more discretely at the peptide level, a
multivariate analysis approach using hierarchical clustering and heat-map
annotation was used incorporating linear mixed modeling of the data to control
for fixed and random variables. Lastly, univariate (pair-wise t-tests with
Benjamini-Hochberg correction for multiple comparisons) were used to establish
differences in peptide groups and individual peptides across patient cohorts.
Peptide abundance differences were plotted as log2FC versus –log10 BH-
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corrected p-value. Peptides with BH-corrected p-value < 0.05 and log2FC ≥ 1
were considered significantly upregulated, and peptides with BH-corrected pvalue <0.05 and log2FC ≤ -1 were considered significantly downregulated. The
Tukey's HSD test was used for all pairwise comparisons. Pairwise comparisons
were illustrated for the major comparators of: A. Healthy vs. Mild-A, B. Healthy
vs. Mild-B, C. Healthy vs. Moderate, D. Healthy vs. Severe, E. Mild-A vs Mild-B,
F. Moderate vs. Severe. Prior to statistical comparisons, these data were
adjusted for (a) random effects by correcting in a sample dependent fashion to
iRT peptide AUCs and sample flight number and (b) fixed effects by correcting
for age and sex. The peptides demonstrating differential abundance (regulated)
in the pair-wise t-testing (BH-corrected p-value <0.05) were aggregated and
filtered using the Matrix Annotator (http://matrisomeproject.mit.edu/analyticaltools/matrisome-annotator/) by GO assignment for ECM. The identification of
regulated ECM peptides common to all or unique between AH, AUD, and healthy
control groups were determined graphically (regulated ECM peptidome).

3. Statistical analysis of renal cortex proteomic and transcriptomic data
Statistical analyses of proteomic and transcriptomic data used one-way
ANOVA and post-hoc t-tests corrected for multiple comparisons by the method of
Benjamini-Hochberg, and a corrected p-value (q-value) of less than 0.05 was
considered significant. Analysis of immunoblot data used two-way ANOVA to
determine interaction effects of diet (EtOH) and treatment (LPS) with post-hoc ttest to determine significance of differences between group means with a p-value
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≤ 0.05 considered significant. Statistical analyses used to determine significance
of proteins or genes with canonical pathways, gene ontological associations, and
pathway clustering were as embedded within Ingenuity Pathways Analyses
(analysis.ingenuity.com), MetaCore (genego.com), Gene Ontology/GO
(patherdb.org) and Heatmapper (heatmapper.ca).
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CHAPTER III

THE HEPATIC “MATRISOME” RESPONDS DYNAMICALLY TO INJURY:
CHARACTERIZATION OF TRANSITIONAL CHANGES TO THE
EXTRACELLULAR MATRIX IN MICE1

A. Introduction
Although the structural role of the ECM is well known, this compartment
contains a diverse range of components that work bidirectionally with
surrounding cells to create a dynamic and responsive microenvironment. This
microenvironment, in turn, regulates cell and tissue homeostasis. ECM
components are directly involved in signaling through interactions with cellsurface receptors. The ECM also indirectly impacts cell-to-cell communication by
binding and retaining soluble mediators, including cytokines, chemokines, and
growth factors (18). Proteases and protease inhibitors interact with the ECM to
maintain homeostasis or respond to stress or injury.(21) A broader definition of
the ECM proteome (i.e., “‘matrisome”‘) has been established to encompass not

1

Published in 93.
Massey VL, Dolin CE, Poole LG, Hudson SV, Siow DL, Brock GN,
Merchant ML, Wilkey DW, Arteel GE. The hepatic "matrisome" responds dynamically to injury:
Characterization of transitional changes to the extracellular matrix in mice. Hepatology.
2017;65(3):969-82. Epub 2016/12/31. doi: 10.1002/hep.28918. PubMed PMID: 28035785;
PMCID: PMC5319876. Reprint with permission.
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only fibrillar ECM proteins, but also the proteins that contribute to the
homeostasis of the ECM proteome.(18)
In some contexts, changes to the ECM are well recognized and understood;
for example, the formation of collagenous scars in tissue is almost a canonical
response to unresolved chronic injury. Hepatic fibrosis (HF) is a well-known
example of this scarring process,(45) given that fibrotic livers develop easily
detectable collagenous scars. Given the dominance of these changes in the
hepatic ECM during fibrogenesis, many studies have focused on the
mechanisms that underlie the increases in collagen deposition. However, the
alterations of the hepatic ECM during fibrosis are much more diverse than simply
an increase in collagen. Indeed, fibrosis is characterized by changes in the
deposition and distribution of a myriad of other ECM proteins (e.g., laminin and
vitronectin).(111) Whereas many of these changes are described, there are still
gaps in our understanding. Specifically, the magnitude and impact of these
changes on overall liver (dys)function are incompletely understood at this time.
ECM remodeling limited to chronic fibrogenesis, but also plays a role in early
injury responses; the wound-healing response is a well-known example of this.
The term “transitional tissue remodeling” describes changes to the ECM that do
not alter the overall architecture of the organ (Fig. 3.1A). For example, changes
in the hepatic abundance of ECM proteins, such as fibronectin(90) and fibrin,(89,
112) have been observed in models of hepatic inflammation. Importantly,
blocking these ECM changes blunts, at least in part, hepatic injury in these
models. Therefore, transitional changes to the ECM may contribute to early
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disease initiation and/or progression before the onset of fibrogenesis (Fig. 3.1A).
The nature, breadth, and magnitude of these ECM changes are currently poorly
understood. A better understanding could forward new mechanisms and/or
biomarkers for diseases.
Although previous studies have shown that subtle changes in the ECM
may contribute to the development of inflammatory liver injury, the research in
this area has generally been restricted to study of single ECM proteins (e.g.,
fibrin). (89, 112) A proteomic approach was hindered by the challenges of low
abundance and insolubility of many ECM proteins, until the recent development
of a new method. This method involves a sequential protein extraction using
increasingly rigorous solubilization buffers along with LC-MS/MS analysis.(92,
99, 113) The sequential extraction was specifically designed to enrich and
characterize ECM proteins in solid organs. This approach also potentially
accounts for proteins that can exist in different solubility states, based on
posttranslational modifications (e.g., cleavage, cross-linking, and degradation).
The goals of the current study were 2-fold: (1) to characterize the sequential
extraction method for hepatic matrisome and (2) to compare the impact of
inflammatory liver injury (before fibrosis) on the hepatic matrisome.

B. Experimental Procedures
1. Animals and exposures
Mice were exposed to CCl4 as described in Chapter II. Mice were exposed to
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Figure 3.1: Scheme of transitional ECM changes and extraction
methodology.

Remodeling in response to chronic injury (i.e., fibrosis) is well known; however,
the hepatic ECM also responses dynamically to acute stress. These acute
responses can be viewed as an arm of the wound‐healing response and facilitate
recovery from damage, which resolves once the damage is repaired. However,
under conditions of chronic injury, these changes contribute to activation of a
significant remodeling response that leads to scar formation (i.e., fibrosis).

47

Healthy Liver

A

Acute Injury

Transitional ECM

Chronic Injury

Inflammation
Injury

ECM
Homeostasis

Injury Resolution

B
Tissue
sample

NaCl

SDS

Loosely bound
ECM proteins

GnHCl

Pellet

Fibrillar ECM proteins

Crosslinking and ‘age’

48

Fibrotic ECM

ethanol and/or LPS also as described in Chapter II. 6 control mice, 5 ethanol
mice, 6 24h LPS mice, and 4 ethanol+24h LPS mice were used for the hepatic
matrisome analysis.

2. Three-step ECM extraction
Liver tissue was submitted to a 3-step extraction process that allows
sequential isolation of loosely-bound extracellular proteins, cellular proteins,
tightly bound extracellular proteins, and highly crosslinked, insoluble proteins to
be differentially separated as described in Chapter II.

3. Sample cleanup and preparation for liquid chromatography and
mass spectrometry
Liver tissue extracts were prepared for LC-MS/MS analysis as described in
Chapter II.

4. Liquid chromatography and mass spectrometry
Liver tissue extracts underwent LC-MS/MS analysis as described in Chapter
II.

5. Data analysis
LC-MS/MS data were analyzed as described in Chapter II.

6. Statistical analysis
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Statistical analysis was performed as described in Chapter II.

C. Results
1. Analysis of changes to the ECM proteome caused by CCl4-induced
hepatic fibrosis
Previous studies have investigated the matrisome profile for aortic vessel and
cardiac tissue (99, 114). However, this method has never been employed for
liver tissue. The first objective of this work was to validate this multi-step
extraction and proteomic analysis of the hepatic matrisome; toward this end, a
model that causes robust changes to the hepatic ECM (i.e., fibrosis) was used.
Specifically, the impact of 4 weeks of CCl4 exposure (see Experimental
Procedures) on the ECM proteome was determined (Fig. 3.2). As expected,(96)
CCl4 exposure caused robust ECM deposition that was easily detected with
standard collagen staining (Sirius Red/Fast Green; Fig. 3.2A), dot blot, and
hydroxyproline content (Fig. 3.2B). The proteomic approach reinforced an
increase in collagen 1α1 abundance with CCl4 (Fig. 3.2C). Additionally, the
proteomic approach demonstrated that CCl4 exposure also increased abundance
of collagens type III, IV, and V (Fig. 3.2C).
Proteomic analysis is typically carried out on total protein extracts, as
opposed to extracts from multi-step fractionation. To simulate this approach,
qualitative proteomic data from the different fractions (see Experimental
Procedures) were pooled. The majority of ECM proteins were detected in
extracts of livers of both naïve and CCl4‐exposed mice. Specifically, CCl4
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Figure 3.2: Validation of extraction technique with CCl4 model of fibrosis.

Animals were injected with CCl4 or vehicle for 4 weeks. Collagen type I
accumulation was determined by Sirius Red staining (A) and by dot blot (control
n=4, CCl4 n=4) and hydroxyproline content (control n=4, CCl4 n=6) (B).
Quantitative changes in other collagens were also determined in the ECM
extraction fractions (control n=1 pooled sample of 6, CCl4, 1 pooled sample of 5)
(C). Abbreviations: COL, collagen; GAPDH, glyceraldehyde 3‐phosphate
dehydrogenase.
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exposure increased the number of ECM proteins by 7, and only one protein was
lost compared to the control group (data not shown). These data indicate that,
when analyzed as a whole, there are few qualitative changes (i.e.,
disappearance or appearance of proteins) in the hepatic matrisome, even under
conditions of significant histological ECM changes (e.g., fibrosis; Fig. 3.2A).

2. Ethanol and LPS exposure cause global changes to the hepatic
matrisome
After validation of the multi-step extraction method with CCl4‐challenged livers
(Fig. 3.2), a more detailed analysis of the effects of ethanol and LPS was carried
out. Figure 3.3A shows a heatmap comparing the quantitative changes in the
ECM proteome between the four exposure groups (±ethanol diet, ±LPS injection)
after fractions were combined ‘in silico’; the most up‐regulated or down‐regulated
ECM proteins were used to compare the groups. Heatmap visualization of the
ECM proteomes demonstrates distinct segregation between the control group
and exposure groups, with ethanol and LPS exposure groups producing varying
patterns; ethanol + LPS produced patterns similar to both exposures alone, but
also demonstrated unique patterns (Fig. 3.3A). However, similar to the CCl4
qualitative analysis (see above and Fig. 3.2), ethanol and/or LPS caused only a
small number of proteins to change qualitatively.

3. Three-step serial extraction creates distinct protein profiles
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Figure 3.3: Liver extracts have unique protein profiles based on fraction
type and experimental group.
A heatmap depicting quantitative changes to the total ECM proteome in response
to ethanol or LPS is shown in (A). The number of proteins unique to, or shared
by, all four extractions of pair-fed animals is shown (B). Bubble graphs are used
to show presence of plasminogen, Annexin A1 and fibrin(ogen) gamma chain
across the four extracts (x-axis) and the four experimental groups (y-axis; C).
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ECM proteins are not only regulated at the level of de novo synthesis, but
also at the level of enzymatic activation, degradation, and crosslinking. To gain
insight into protein location and structure, previous studies have used a three‐
step ECM extraction method (Fig. 3.1B) in other organs. (99, 114) Here, that
same approach was adapted for use with liver tissue. In the first step of this
extraction, NaCl extraction solubilizes loosely bound proteins by displacing
polyionic interactions. (115) Following NaCl extraction, the remaining liver tissue
was decellularized using 1% sodium dodecyl sulfate (SDS). SDS solubilizes
cytoplasmic and nuclear membranes, thereby releasing cellular proteins.
Insoluble matter remaining after the decellularization then underwent extraction
with a denaturing 4 M GnHCl buffer.(116) Following the denaturing extraction,
an insoluble pellet enriched in heavily cross‐linked matrix proteins
remained.(114) Fig. 3.3B shows a qualitative comparison of the four extracts of
ECM proteins from control animals. Each extract yielded a distinct ECM protein
profile consisting of not only ECM proteins that were shared among all four
extracts, but also proteins unique to specific extracts (Fig. 3.3B). Analysis of the
CCl4 extracts for collagen isoforms (Fig. 3.2C) indicated that, as expected, these
proteins tended to accumulate in the later extraction fractions. These results
indicate that the extraction approach effectively separated ECM proteins.
When ECM proteins were compared between experimental groups,
interesting patterns of distribution across the extracts were revealed (Table 3.1);
representative examples of some of these patterns are shown in Fig. 3.3C. For
example, some proteins (e.g., plasminogen) changed in overall “presence” or
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Table 3.1: Qualitative presence of ECM proteins in sample extracts

Accession
Number

Protein name

MW
(kDa)

ECM function

Ref

Presence of protein

Proteoglycans and glycoproteins
Alpha-1-acid glycoprotein 1

A1AG1_MOUSE

24

Acute phase serum protein

(201)

Alpha-2-HS-glycoprotein

FETUA_MOUSE

37

Inhibitor of ECM mineralization

(202)

57
Arylsulfatase A

ARSA_MOUSE

54

ECM structure

(203)

Beta-2-glycoprotein

APOH_MOUSE

39

Coagulation, phospholipid
binding

(204)

Biglycan

PGS1_MOUSE

EtOH

LPS

EtOH
+LPS

█

█

█

█

█

█

█

█

█

█

█

Con

42

Regulation of collagen fibril
formation, ECM-cell
interactions

(205)

Corneodesmosin

CDSN_MOUSE

54

Adhesive protein

(206)

Cysteine-rich with EGF-like
domain protein 2

CREL2_MOUSE

38

Extracellular protein heavily
glycosylated. ECM
function unknown

(207)

NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█

█

█

█

█

█

█

█

█

█
█

█

█
█

█

█

█

█

█

Decorin

Dermatopontin

Dystroglycan

Fibrinogen alpha chain

PGS2_MOUSE

DERM_MOUSE

DAG1_MOUSE

E9PV24_MOUSE

40

24

97

87

ECM-cell interactions, ECM
assembly

ECM-cell interactions, ECM
assembly

Matrix organization, basement
membrane assembly

Hemostasis, cell signaling
(fibrin(ogen) alpha chain)

(208)

(209)

(210)

(211)

58
Fibrinogen beta chain

FIBB_MOUSE

55

Hemostasis, cell signaling

(211)

Fibrinogen gamma chain

FIBG_MOUSE

49

Hemostasis, fibrinogen
polymerization

(212)

Fibronectin

Galectin-1

Galectin-3-binding protein

FINC_MOUSE

LEG1_MOUSE

LG3BP_MOUSE

273

15

64

Scaffolding, ECM organization,
regulation of ECM-cell
interactions

(213)

Matrix crosslinking, matrix
organization

(214)

Cell-matrix adhesion

(215)

NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet
NaCl
SDS
GnHCl
Pellet

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█

█
█
█

█

█

█

█
█
█
█

█
█
█
█
█

█
█

█

█
█
█

█

█

█

█

█

█

█

█

█
█
█

█

█

█
█

█
█
█

█
█
█

█

Granulins

GRN_MOUSE

63

Cell-matrix signaling

(216)

Haptoglobin

HPT_MOUSE

39

Inhibition of collagen
degradation, cell migration

(217)

Insulin-like growth factorbinding protein 2

IBP2_MOUSE

33

Binding/retainment of ILGF in
the extracellular space

(218)

59

Insulin-like growth factorbinding protein 4

IBP4_MOUSE

28

Binding/retainment of ILGF in
the extracellular space

(218)

Keratin, type I cytoskeletal 13

K1C13_MOUSE

48

Cell-matrix adhesion, cell
migration

(219)

Leucine-rich HEV
glycoprotein

Q91XL1_MOUSE

37

Cell-matrix adhesion

(220)

Lumican

LUM_MOUSE

38

Regulation of collagen fibril
formation

(221)

Microfibrillar-associated
protein 5

Fibrinogen alpha chain

MFAP5_MOUSE

E9PV24_MOUSE

18

87

Elastic fiber assembly, binding
of fibrillin-1 and fibrillin-2

Hemostasis, cell signaling
(fibrin(ogen) alpha chain)

(222)

(211)
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Ribonuclease inhibitor

RINI_MOUSE

50

Extracellular inhibitor of
angiogenin which can
degrade BM

(223)

Sulfated glycoprotein 1

SAP_MOUSE

61

Cell survival, cell signaling

(224,
225)

Syndecan-4

60

Tubulointerstitial nephritis
antigen-like

Vitronectin

SDC4_MOUSE

TINAL_MOUSE

VTNC_MOUSE

21

52

55

ECM organization, signal
transduction, cell adhesion

(226)

Protein binding - fibronectins,
collagens

(227)

ECM-cell signal transduction,
cell adhesion

(228)
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Other ECM-associated proteins
14-3-3 protein epsilon
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Con

1433E_MOUSE

29

Protein binding

(229)
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EtOH

█

LPS

EtOH
+LPS
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█

SDS
GnHCl

14-3-3 protein gamma

14-3-3 protein sigma

1433G_MOUSE

1433S_MOUSE

28

28

Protein binding

Protein binding

(229)

(229)

Pellet
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SDS
GnHCl
Pellet
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GnHCl
Pellet

█

█

14-3-3 protein zeta/delta

1433Z_MOUSE

28

Protein binding

(229)

Actin, cytoplasmic 1

ACTB_MOUSE

42

Cortical cytoskeleton

(230,
231)

Actin, cytoplasmic 2

ACTG_MOUSE

42

Cortical cytoskeleton

(230,
231)

61

Alpha-2-macroglobulin
receptorassociated protein

AMRP_MOUSE

42

Protein binding, soluble
mediator internalization

(232)

Alpha-actinin-4

ACTN4_MOUSE

105

Focal adhesion, cell adhesion

(233,
234)

Annexin A1

ANXA1_MOUSE

39

ECM binding, fibrinolysis

(235)

Annexin A2

ANXA2_MOUSE

39

ECM binding, fibrinolysis

(236)

Annexin A5

ANXA5_MOUSE

36

ECM binding (collagen)

(237)

Apolipoprotein A-I

APOA1_MOUSE

31

ECM binding (collagen,
fibronectin)

(238)
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Apolipoprotein A-IV

Apolipoprotein E

APOA4_MOUSE

APOE_MOUSE

45

36

Apolipoprotein O-like

APOOL_MOUSE

29

Beta-2-microglobulin

B2MG_MOUSE

14

Lipid metabolism

Lipid metabolism, cell signaling

(239)

(240)

62

Protein binding, cell-ECM
interaction

(241)

Calreticulin

CALR_MOUSE

48

Protein binding (collagens,
laminin)

(242)

Calumenin

CALU_MOUSE

37

Pprotein binding, stabilization of
fibulin-1

(243)

Carbonic anhydrase 2

CAH2_MOUSE

29

pH regulation of ECM (other
isozymes)

(244)

Ceruloplasmin

CERU_MOUSE

121

Iron, copper binding

(245)

Chitinase-like protein 3

CHIL3_MOUSE

44

ECM turnover

(246)
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Clusterin

Cofilin-1

CLUS_MOUSE

COF1_MOUSE

52

19

Extracellular protein chaperone

Cortical cytoskeleton, cell
motility

(247)

(248)

CRP_MOUSE

25

Protein binding (fibronectin)

(249)

C-X-C motif chemokine 9

CXCL9_MOUSE

14

Soluble mediator (angiostatic
cytokine)

(250,
251)

63

C-reactive protein

Endoplasmin

ENPL_MOUSE

92

Soluble mediator (TLR
signaling)

(252)

Estradiol 17-betadehydrogenase 12

DHB12_MOUSE

35

Protein binding (heparin,
fibronectin, collagen)

(253)

Ferritin heavy chain

FRIH_MOUSE

21

Cell migration

(254)

Ferritin light chain 1

FRIL1_MOUSE

21

Cell migration

(254)

Glucose-6-phosphate
isomerase

G6PI_MOUSE

63

Cell motility

(255)
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Hepatoma-derived growth
factor

High mobility group protein
B1

HDGF_MOUSE

HMGB1_MOUSE

26

25

Decreted heparin-binding
growth factor

Heparin binding, cytokine

(256)

(257,
258)

HMGB2_MOUSE

24

Heparin binding, cytokine

(257,
258)

Lumican

LUM_MOUSE

38

Regulation of collagen fibril
formation

(221)

Moesin

MOES_MOUSE

68

Cell cortex organization

(259)

Myosin-9

MYH9_MOUSE

226

Cell migration, cortical actin
organization

(260)

ECM remodeling (modulation of
MMP9 activity)

(261)

64

High mobility group protein
B2

Neutrophil gelatinaseassociated
lipocalin

NGAL_MOUSE

Nucleobindin-2

NUCB2_MOUSE

Peptidyl-prolyl cis-trans
isomerase A

PPIA_MOUSE

23

50

18

Matrix maturation

Matrix assembly of hensin

(262)

(263)
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Pro-cathepsin H

CATH_MOUSE

37

Matrix degradation

(264)

S100-A13

S10AD_MOUSE

11

Calcium binding

(265)

S100-A9

Serum amyloid A-1

SAA1_MOUSE

14

Cell adhesion

(266)

65
Serum amyloid A-2

Serum amyloid A-3

SAA2_MOUSE

SAA3_MOUSE

14

14

Cell adhesion

Cell adhesion

(266)

(266)

Serum amyloid P-component

SAMP_MOUSE

26

Protein binding (type IV
collagen, laminin)

(267,
268)

Superoxide dismutase [CuZn]

SODC_MOUSE

16

Protein binding
(heparin/heparan sulfate,
type 1 collage)

(269)

Thioredoxin

THIO_MOUSE

12

Soluble mediator
(immunomodulatory
cytokine)

(258)
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Tubulin beta-5 chain

TBB5_MOUSE

50

Microtubule formation, modified
via ECM interactions

(231)

UPF0556 protein C19orf10
homolog

CS010_MOUSE

18

Soluble mediator (cytokine)

(270)

Vimentin

VIME_MOUSE

54

Microtubule formation

(271)

Vitamin D-binding protein

VTDB_MOUSE

54

Vitamin D binding

(272)

66
Proteases and protease inhibitors
Alpha-1-antitrypsin 1-1

A1AT1_MOUSE

46

Inhibition of ECM proteases;
inhibition of trypsin

(273)
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EtOH

LPS

EtOH
+LPS
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SDS
GnHCl

Alpha-1-antitrypsin 1-4

A1AT4_MOUSE

46

Inhibition of ECM proteases;
inhibition of trypsin

AMBP

AMBP_MOUSE

39

Precursor of protein HC
(protein-ECM interactions) &
bikunin (protease inhibitor),

(274276)

Inhibition of ECM proteases,
inhibition of ADAMTS-7
and ADAMTS-12

(277)

Alpha-2-macroglobulin

A2M_MOUSE

166

(273)
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Antithrombin-III

Cathelin-related
antimicrobial peptide

ANT3_MOUSE

CRAMP_MOUSE

52

20

Inhibition of ECM proteases,
inhibition of thrombin

(278)

Inhibition of ECM proteases,
inhibition of cathepsin Lcysteine protease activity

(279)

Cathepsin B

CATB_MOUSE

37

ECM degradation

(264)

Cathepsin D

CATD_MOUSE

45

ECM degradation, activation of
cathepsin B

(280)

67
Cathepsin Z

CATZ_MOUSE

34

ECM degradation, integrin
signaling

(281,
282)

Complement C3

CO3_MOUSE

186

Activation of complement
system

(283)

Protein cleavage (cytokines,
chemokines), protein
binding (collagen)

(284)

Dipeptidyl peptidase 4

DPP4_MOUSE

87

Ectonucleoside triphosphate
diphosphohydrolase 5

ENTP5_MOUSE

47

Hydrolysis of extracellular ATP

(285)

Fetuin-B

FETUB_MOUSE

43

Cysteine protease inhibitor,
metalloprotease inhibitor,
matrix mineralization

(286,
287)
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Gelsolin

GELS_MOUSE

86

Actin filament capping

(288)

Ectonucleoside triphosphate
diphosphohydrolase 5

ENTP5_MOUSE

47

Hydrolysis of extracellular
ATP/ADP (signaling)

(286)

Hemopexin

HEMO_MOUSE

51

Heme binding

(289)

IDE_MOUSE

118

Metalloendopeptidase

(290)

Inter alpha-trypsin inhibitor,
heavy chain 4

ITIH4_MOUSE

100

Chain of ITI (protease inhibitor)

(291)

Lysozyme C-1

LYZ1_MOUSE

17

Antibacterial, hydrolysis of β-1,
4-glycosidic linkages

(292)

Lysozyme C-2

LYZ2_MOUSE

17

Antibacterial, hydrolysis of β-1,
4-glycosidic linkages

(292)

Murinoglobulin-1

MUG1_MOUSE

165

Protease inhibitor

(293,
294)

68

Insulin-degrading enzyme

Myeloid bactenecin (F1)

O08692_MOUSE

19

Cysteine protease inhibitor

(295)
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Phosphatidylethanolaminebinding protein 1

Plasminogen

PEBP1_MOUSE

PLMN_MOUSE

21

91

Serine protease inhibitor

Precursor of plasmin (serine
protease)

(296)

(297)

P20D1_MOUSE

56

Serpinb9

O08797_MOUSE

42

Serine protease inhibitor,
granzyme inhibitor)

(298)

Serine protease inhibitor
A3K

SPA3K_MOUSE

47

Serine protease inhibitor,
chymotrypsin inhibitor

(299)

Serine protease inhibitor
A3N

SPA3N_MOUSE

47

Serine protease inhibitor,
chymotrypsin inhibitor

(299)

Serpin B5

SPB5_MOUSE

42

Serine protease inhibitor,

(299)

Thioredoxin

THIO_MOUSE

12

Activation of transglutaminase

(300)

69

Probable carboxypeptidase
PM20D1

Transthyretin

TTHY_MOUSE

16

Hormone binding protein,
cryptic protease,
peptidase

(301)
(302)
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Collagens
Adiponectin

Collagen alpha-1(I) chain

Collagen alpha-1(III) chain

70

Collagen alpha-1(IV) chain

ADIPO_MOUSE

CO1A1_MOUSE

CO3A1_MOUSE

CO4A1_MOUSE

27

138

139

161

Inhibition of vascular matrix
degradation (contains
collagen-like domain)

(303,
304)

Component of collagen fibrins

(303)

Component of collagen fibrils

Component of collagen network

(303)

(303)

CO5A1_MOUSE

184

Fibrillogenesis, crosslinking

(303)

Collagen alpha-2(I) chain

CO1A2_MOUSE

130

Component of collagen fibrils
(contains collage-like
domain)

(303)

Collagen alpha-2(IV) chain

CO4A2_MOUSE

167

Component of collagen network

(303)

Collagen alpha-2(V) chain

CO5A2_MOUSE

145

Fibrillogenesis, crosslinking

(303)

MBL2_MOUSE

26

soluble pattern recognition
receptor

EtOH

LPS

EtOH
+LPS
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GnHCl

Collagen alpha-1(V) chain

Mannose binding protein

NaCl

Con
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Extracellular - ECM interactions unknown
60 heat shock protein,
CH60_MOUSE
mitochondrial

61

71

78 glucose-regulated
protein

GRP78_MOUSE

72

Aminoacyl tRNA synthase
complex-interacting
multifunctional
protein 1
Arginase-1

AIMP1_MOUSE

34

ARGI1_MOUSE

35

BolA-like protein 1

BOLA1_MOUSE

14

BolA-like protein 3

BOLA3_MOUSE

12

Carboxylesterase 1C

EST1C_MOUSE

61

Clathrin heavy chain 1

CLH1_MOUSE

192

Epididymal secretory protein
E1

NPC2_MOUSE

16

Group XIIB secretory
phospholipase A2-like
protein
Heat shock cognate 71
protein

Q8VC81_MOUSE

22

HSP7C_MOUSE

71

Hepcidin

HEPC_MOUSE

9

Hypoxia up-regulated protein
1

HYOU1_MOUSE

111

IIGP1_MOUSE

48

Lactotransferrin

TRFL_MOUSE

78

Macrophage migration
inhibitory factor

MIF_MOUSE

13

Major urinary protein 12

A2CEK7_MOUSE

21

Major urinary protein 17

MUP17_MOUSE

21

Major urinary protein 20

MUP20_MOUSE

21

Major urinary protein 3

MUP3_MOUSE

21

Major vault protein

MVP_MOUSE

96

Monocyte differentiation
antigen CD14

CD14_MOUSE

39

Multiple coagulation factor
deficiency protein 2
homolog
Myeloperoxidase

MCFD2_MOUSE

16

PERM_MOUSE

81

Nuclease-sensitive elementbinding protein 1

YBOX1_MOUSE

36

Polymeric immunoglobulin
receptor

PIGR_MOUSE

85

Profilin-1

PROF1_MOUSE

15

72

Interferon-inducible GTPase
1

CREG1_MOUSE

24

Protein Gm20425

E9Q035_MOUSE

108

Pyruvate kinase PKM

KPYM_MOUSE

58

RNA binding motif protein,
X-linked-like-1

RMXL1_MOUSE

42

Serotransferrin

TRFE_MOUSE

77

Serum albumin

ALBU_MOUSE

69

Serum
paraoxonase/arylesterase
1
Translationally-controlled
tumor protein

PON1_MOUSE

40

TCTP_MOUSE

19

UPF0369 protein C6orf57
homolog

CF057_MOUSE

12

Xanthine
dehydrogenase/oxidase

XDH_MOUSE

147

73

Protein CREG1

“absence” in response to exposures, but localized consistently to the same
fraction when present. Ethanol and/or LPS exposure caused other proteins to
appear in different extracts in simple or complex patterns. For example, whereas
Annexin A1 was found in the insoluble pellet from control animals, it was not
detected in any fraction from animals exposed to ethanol or LPS alone; however,
the combination of ethanol and LPS caused this protein to accumulate in the
NaCl fraction. Similarly, fibrin(ogen) gamma chain was found in all experimental
groups, but its fractionation pattern was unique to each exposure condition.
These patterns likely represent differences in the synthesis, degradation, and/or
maturity of the ECM proteins.

4. Qualitative changes to the ECM proteome in response to stress
Figure 3.4 summarizes the abundance of ECM proteins, organized by
category (i.e., glycoproteins and proteoglycans (Fig. 3.4A), ECM‐associated
proteins (Fig. 3.4B), proteases and inhibitors (Fig 3.4C), and collagens (Fig.
3.4D)) across the four extraction conditions. The majority of the proteins in the
NaCl and SDS extracts were ECM‐associated proteins (Fig. 3.4A); this was
unsurprising, given that proteins in this category are generally loosely associated
with the ECM and are therefore easily solubilized. Additionally, the low
abundance of collagens in the NaCl and SDS fractions (Fig. 3.4D) was not
surprising, given that collagens are often tightly cross‐linked and require
denaturing conditions for solubilization. As expected, the denaturing conditions
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Figure 3.4: Ethanol and LPS cause dynamic changes in the matrisome.
The impact of ethanol diet (left panels) and 24-hour LPS (right panels) on the
types of proteins found in the ECM proteome are shown. Proteins are
categorized by class (A-D) and organized by extraction fraction (NaCl, SDS,
GnHCl, and pellet). Red proteins indicate those that appeared with exposure,
whereas green proteins indicate those that were lost with exposure, compared to
control.
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created by GnHCl more than doubled the number of proteoglycans and
glycoproteins in that extract compared to the NaCl and SDS fractions. The
number of collagens in the GnHCl extract was also dramatically increased
compared to the NaCl and SDS fractions. The pellet fraction contained the
fewest proteins of all four extracts but contained the greatest number of
collagens.
Ethanol and/or LPS exposure did not change the general pattern of proteins
found in the various extracts (Fig. 3.4), but both tended to increase the total
number of ECM proteins in the fractions combined. For example, ethanol
exposure caused a net increase in the number of ECM proteins by ∼25%. These
changes were predominantly spread across the first three protein classes, with
the NaCl, SDS, and GnHCl extracts all increasing evenly. The pellet fraction
responded the least dynamically to ethanol or LPS exposure and actually
showed a net loss in total proteins. Likewise, collagens were the least
responsive protein class (Fig. 3.4D). Figure 3.5 (left panels) shows the
distribution of the proteins in the various extracts between all four exposure
groups.
In addition to proteins that changed in their extraction pattern in response
to ethanol (e.g., see Fig. 3.3C), there were several proteins that were uniquely
detected with ethanol exposure compared to control (Figs. 3.4 and 3.5); these
include fibrin(ogen) α and β chains, cytokeratin 13, vitronectin, plasminogen, high
mobility group protein B2, and collagens IVα2 and Vα2 (see Table 3.1). Similarly,
LPS exposure caused the appearance of several proteins that were unique
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Figure 3.5: Shared and unique changes to the hepatic matrisome.

Venn diagrams (left column) show all ECM proteins within each of the four
extracts and indicate the number that are shared between, or that are unique to,
the four experimental groups. Bubble plots (right column) show quantitative
changes in abundance of proteins that were shared by all four experimental
groups. The bubble plots show fold of control in protein abundance caused by
LPS (y-axis), ethanol (x-axis), and the combination of ethanol + LPS (bubble
size). Each bubble represents a protein; bubble color indicates the protein’s
class.

78

79

compared to control (Figs. 3.4 and 3.5). Several of these proteins were the same
as those detected with ethanol exposure, but several were unique to LPS,
including serpine B5 (maspin), serine protease inhibitor A3N, and CXC motif
chemokine ligand 9 (see Fig. 3.5; Table 3.1).
Previous work has shown that ethanol preexposure sensitizes the liver to
inflammatory injury caused by a second insult (i.e., LPS) (26, 117). Furthermore,
previous studies have suggested that changes in ECM composition can
contribute to the sensitizing effect of ethanol preexposure (89). In this study, the
combination of chronic ethanol exposure and a second hit of LPS caused unique
changes in the ECM protein profile of the liver. The combination of EtOH+LPS
resulted in the appearance of four unique proteins that were not detected in livers
from animals exposed to either ethanol or LPS alone, including serum amyloid P
and serpine B9.

5. Quantitative changes to the ECM proteome in response to stress
Dramatic changes to the ECM (i.e., “lost” or “gained” proteins) can
significantly affect overall organ function; it is not surprising that the majority of
the matrisome did not change at the qualitative level. However, several of these
proteins did change in relative abundance in response to ethanol and/or LPS
compared to control (Figs. 3.5 and 3.6). Figs. 3.7‐3.10 provide results of the
clustering analysis of the protein abundances for each fraction. Based on this
analysis, six clusters were identified as the best visual representation of the data.
Table 3.2 identifies the membership of each protein within each cluster. Notable
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Figure 3.6: Quantitative changes to the matrisome.

Heatmap analysis of the quantitative changes in abundance of proteins that were
shared by all four experimental groups (see Fig. 3.5) are shown for the NaCl (A),
SDS (B), GnHCl (C), and pellet (D) extraction fractions.
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Figure 3.7: Clustered profiles of protein abundances for proteins identified
in the NaCl fraction.

Abundance values for each protein were first standardized to a mean of zero and
a standard deviation of one prior to clustering. See also Table 3.2.
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Figure 3.8: Clustered profiles of protein abundances for proteins identified
in the SDS fraction.
Abundance values for each protein were first standardized to a mean of zero and
a standard deviation of one prior to clustering. See also Table 3.2.
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Figure 3.9: Clustered profiles of protein abundances for proteins identified
in the GnHCl fraction.

Protein abundances were first standardized to a mean zero and a standard
deviation one for each protein prior to clustering. See also Table 3.2.
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Figure 3.10: Clustered profiles of protein concentrations for proteins
identified in the pellet.

Abundance values for each protein were standardized to a mean of zero and a
standard deviation of one prior to clustering. See also Table 3.2.
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Table 3.2: Clustering of proteins in response to ethanol and/or LPS
NaCl fraction
Protein

Class

14-3-3 protein epsilon

other ECM proteins

1

Apolipoprotein A-I

other ECM proteins

1

Carbonic anhydrase 2

other ECM proteins

1

Cysteine-rich with EGF-like domain protein

proteoglycans and glycoproteins

1

Granulins

proteoglycans and glycoproteins

1

Hepatoma-derived growth factor

other ECM proteins

1

Moesin

other ECM proteins

1

Murinoglobulin-1

proteases and protease inhibitors

1

Peptidyl-prolyl cis-trans isomerase A

other ECM proteins

1

Antithrombin-III

proteases and protease inhibitors

2

Dystroglycan

proteoglycans and glycoproteins

2

Ferritin light chain 1

other ECM proteins

2

proteases and protease inhibitors

2

Serine protease inhibitor A3K

proteases and protease inhibitors

2

Superoxide dismutase [Cu-Zn]

other ECM proteins

2

Thioredoxin

other ECM proteins

2

Transthyretin

proteases and protease inhibitors

2

14-3-3 protein zeta/delta

other ECM proteins

3

Actin, cytoplasmic 1

other ECM proteins

3

Alpha-actinin-4

other ECM proteins

3

Cathepsin B

proteases and protease inhibitors

3

Cathepsin Z

proteases and protease inhibitors

3

Ferritin heavy chain

other ECM proteins

3

Phosphatidylethanolamine-binding protein 1
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Cluster

Haptoglobin

proteoglycans and glycoproteins

3

Hemopexin

proteases and protease inhibitors

3

High mobility group protein B1

other ECM proteins

3

Pro-cathepsin H

other ECM proteins

3

14-3-3 protein gamma

other ECM proteins

4

Annexin A5

other ECM proteins

4

Calumenin

other ECM proteins

4

Endoplasmin

other ECM proteins

4

Annexin A2

other ECM proteins

5

Cathepsin D

proteases and protease inhibitors

5

Glucose-6-phosphate isomerase

other ECM proteins

5

Alpha-1-antitrypsin 1-4

proteases and protease inhibitors

6

Calreticulin

other ECM proteins

6

C-reactive protein

other ECM proteins

6

UPF0556 protein C19orf10 homolog

other ECM proteins

6

Vitamin D-binding protein

other ECM proteins

6

Adiponectin

collagens

6

SDS fraction
Cysteine-rich with EGF-like domain protein 2

proteoglycans and glycoproteins

1

Ferritin light chain 1

other ECM proteins

1

Actin, alpha skeletal muscle

proteoglycans and glycoproteins other
1
ECM proteins
2

Apolipoprotein A-I

other ECM proteins

2

Apolipoprotein E

other ECM proteins

2

Collagen alpha-1(I) chain

collagens

2

Collagen alpha-2(I) chain
Granulins

collagens
proteoglycans and glycoproteins

2
2

Syndecan-4

Peptidyl-prolyl cis-trans isomerase A other ECM proteins 2 Complement C3 proteases and protease
inhibitors 3
Ferritin heavy chain

other ECM proteins

3

Haptoglobin

proteoglycans and glycoproteins

3

Myosin-9

other ECM proteins

3
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Vimentin
Sulfated glycoprotein 1

other ECM proteins
proteoglycans and glycoproteins

3
4

Actin, cytoplasmic 1

other ECM proteins

5

Calreticulin

other ECM proteins

5

Endoplasmin
Thioredoxin

other ECM proteins
proteases and protease inhibitors

5
5

Beta-2-microglobulin

other ECM proteins

6

Superoxide dismutase [Cu-Zn]
Transthyretin

other ECM proteins
proteases and protease inhibitors

6
6

Vitamin D-binding protein

other ECM proteins

6

Alpha-2-HS-glycoprotein

proteoglycans and glycoproteins

1

Beta-2-glycoprotein 1

proteoglycans and glycoproteins

Decorin

proteoglycans and glycoproteins

1

Ferritin light chain 1

other ECM proteins

1

GnHCl fraction

Lumican

1

1

Mannose-binding protein C

proteoglycans and glycoproteins
collagens

1

Tubulin beta-5 chain

other ECM proteins

1

Vitamin D-binding protein

other ECM proteins

1

Actin, cytoplasmic 2

other ECM proteins

2

Biglycan

proteoglycans and glycoproteins

2

Fibrinogen gamma chain proteoglycans and glycoproteins 2 Fibronectin proteoglycans and glycoproteins 2
Haptoglobin
proteoglycans and glycoproteins
2
Hemopexin

proteases and protease inhibitors

2

Myosin-9
Protein AMBP

other ECM proteins
proteases and protease inhibitors

2
2

Sulfated glycoprotein 1

proteoglycans and glycoproteins

2

Vimentin

other ECM proteins
proteoglycans and glycoproteins

2
3

Apolipoprotein A-I

other ECM proteins

4

Beta-2-microglobulin
Dermatopontin

other ECM proteins
proteoglycans and glycoproteins

4
4

Galectin-1

proteoglycans and glycoproteins

4

Granulins
Hepatoma-derived growth factor

proteoglycans and glycoproteins
other ECM proteins

4
4

Cysteine-rich with EGF-like domain protein 2
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Peptidyl-prolyl cis-trans isomerase A

other ECM proteins

4

Superoxide dismutase [Cu-Zn]
Thioredoxin

other ECM proteins
other ECM proteins

4
4

Collagen alpha-1(I) chain

collagens

5

Collagen alpha-2(I) chain
Syndecan-4

collagens
proteoglycans and glycoproteins

5
5

Alpha-2-macroglobulin receptor-associated
protein

other ECM proteins

6

Calreticulin

other ECM proteins

6

Cofilin-1

other ECM proteins

6

Collagen alpha-1(III) chain

collagens

6

High mobility group protein B1

other ECM proteins

6

Phosphatidylethanolamine-binding protein 1
Transthyretin

proteases and protease inhibitors
proteases and protease inhibitors

6
6

Apolipoprotein A-I

other ECM proteins

1

Apolipoprotein E

other ECM proteins

1

Collagen alpha-1(IV) chain

collagens

1

Granulins

proteoglycans and glycoproteins

1

Endoplasmin

other ECM proteins

2

Sulfated glycoprotein 1

proteoglycans and glycoproteins

2

Actin, alpha skeletal muscle

other ECM proteins

3

Actin, cytoplasmic 1

other ECM proteins

3

Annexin A2
Collagen alpha-1(III) chain

other ECM proteins
collagens

3
4

Superoxide dismutase [Cu-Zn]

other ECM proteins

4

Pellet fraction

Thioredoxin other ECM proteins 5 Collagen alpha-1(I) chain collagens 6
Collagen alpha-2(I) chain

collagens
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6

(>4‐fold increase) changes caused by LPS included ferritin heavy chain (15‐fold
increase) in the NaCl fraction, haptoglobin and myosin‐9 (11‐ and 9‐fold,
respectively) in the SDS fraction, and fibrinogen γ chain and haptoglobin (14‐ and
7‐fold, respectively) in the GnHCl fraction. Likewise, ethanol exposure increased
the abundance of several proteins, including myosin‐9 (6‐fold) and cysteine‐rich
with EGF‐like domain protein 2 (CREDL2; 6‐fold) in the SDS fraction. As was
observed for qualitative analysis (Fig. 3.4), ethanol and/or LPS affected proteins
in the pellet fraction the least of all fractions.
While ethanol alone and LPS alone each changed the abundance of certain
proteins, the combination of the two exposures caused its own unique effects on
the matrisome (Figs. 3.7-3.10). For example, although LPS alone did not change
endoplasmin abundance compared to control, and ethanol only increased it 3‐
fold, the combination of ethanol and LPS increased this endoplasmin abundance
11‐fold in the NaCl fraction (Figs. 3.5 and 3.6). Similarly, the combination of
ethanol and LPS increased granulin abundance 5-fold in the SDS fraction,
despite no effect by ethanol alone and only a 2‐fold increase by LPS (Figs. 3.5
and 3.6). Additionally, although both ethanol alone and LPS alone increased
CRELD2, the combination of ethanol and LPS decreased CRELD2 abundance in
the SDS fraction. Proteins that were differentially regulated by the combination
of ethanol and LPS in the GnHCl fraction include hemopexin and alpha‐1‐
microglobulin/bikunin precursor.

D. DISCUSSION
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This work had two primary goals: (1) to characterize and validate an
extraction and analysis method for the hepatic matrisome that would provide both
the sensitivity to identify low‐abundance proteins and the power to observe global
changes and (2) to use this method to explore transitional (i.e., prefibrotic)
changes to the hepatic matrisome caused by ethanol diet and/or LPS exposure.
As discussed in the Introduction, the study of the hepatic ECM has largely been
“collagenocentric” and “fibrosocentric”—that is, centered on the dramatic
increase in collagen deposition during fibrosis, a quasi‐permanent scarring of the
organ. However, the matrisome of both healthy and diseased liver is exceedingly
more diverse than collagen ECM. Indeed, studies have revealed that in addition
to collagen, laminin (118) and vitronectin (119, 120) are also increased during
fibrogenesis. Furthermore, proteomic studies in other organs have shown that
matrisome composition responds dynamically after insult well before organ
fibrosis.(99, 114, 121) Previously, this group showed that fibrin ECM
accumulation correlates with inflammatory liver injury in several models and may
play a causal role in hepatic damage.(89) Additionally, Gillis et al. (90) have
demonstrated a similar role for fibronectin ECM in experimental ALD. However,
global changes in the hepatic ECM during inflammatory liver injury have not yet
been characterized. The models herein employed (Lieber‐DeCarli ethanol diet
and acute LPS) are well known to cause significant liver damage, but do not
result in histologically detectable changes to the ECM.
Global ECM changes may affect tissue function through three general types
of mechanisms: physical, biochemical, and signaling. Physical properties of the
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ECM include the matrix topography, cross‐linking, and organization.(21) These
physical properties are not only essential to the structural role of the ECM, but
also allow the ECM to either obstruct or facilitate cell migration.(49) Fibrin
matrices have been demonstrated to be permissive to monocyte and leukocyte
chemotaxis and activation.(122, 123) Physical alterations in the ECM can cause
tissue rigidity, resulting in decreased organ function. Although such physical
changes to the ECM can indirectly affect the biochemistry of the liver (e.g.,
hemostasis‐induced hypoxia), matrisome changes can also directly cause
biochemical changes that are independent of structural changes. For example,
ECM components can facilitate ligand-receptor interactions, (124) bind and retain
chemokines,(18) and regulate activation of growth factors (i.e., transforming
growth factor beta). (18) ECM molecules can also directly serve as signaling
molecules through interactions with cell‐surface receptors, including integrins.
(125) Because of the multifaceted roles of many ECM molecules, any single
change in the ECM can, in principle, trigger a cascade of dependent changes
that influence the composition and properties of the ECM. For example, biglycan
acts as a structural component that regulates collagen fiber assembly, but, upon
release from the matrix, can act as a signaling molecule binding to Toll‐like
receptor 4 (TLR4) receptors.(126)
The current study determined the individual and combined effects of two
experimental exposures (ethanol and LPS) on the hepatic matrisome. LPS was
selected because it induces robust hepatic inflammation. The liver is often
exposed to LPS during several pathophysiologic states, including after alcohol
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consumption.(127) Whereas inflammatory responses triggered by small doses of
LPS are typically noninjurious, other stresses can synergistically enhance the
hepatotoxic response to LPS. Indeed, ethanol not only increases circulating
LPS, but also enhances inflammation and liver damage caused by acute LPS
exposure.(117) This “two‐hit” paradigm is common in fatty liver diseases. (64)
In the current study, both stresses caused the hepatic matrisome to respond
dynamically, not only increasing the number of matrisome proteins , but also
differentially changing protein abundance (Fig. 3.5) and likely structure or
location (Figs. 3.4 and 3.5).
Several of the protein changes reported here reiterate results of previous
hypothesis‐driven studies. For example, this work validated that LPS dramatically
alters the fibrin(ogen) ECM, and that ethanol preexposure enhances this effect.
In the current study, LPS exposure increased the relative abundance of
fibrinogen gamma chain in the GnHCl extract. The fibrin(ogen) gamma chain is a
major component of fibrin clots given that it is polymerized into insoluble fibrin
fibers.(128) Therefore, the localization of this robust increase in fibrinogen
gamma chain in the GnHCl fractions suggests that there was an increase in
fibrin(ogen) gamma chain polymerization into a less‐soluble, more highly cross‐
linked form. Furthermore, the combination of ethanol and LPS resulted in
detection of the fibrin(ogen) gamma chain in the insoluble pellet, which suggests
additional modifications that decreased solubility (e.g., cross‐linking). The
appearance of serum amyloid A‐1 and A‐2 proteins in response to LPS was also
confirmed here. (129, 130) In fact, LPS exposure increased the abundance of
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several other acute‐phase proteins, including haptoglobin, complement C, and
ceruloplasmin, which are all known to be increased by LPS exposure. (131-133)
This work also validates previous studies which reported ethanol increased
fibronectin deposition before the onset of fibrosis. (90)
The work herin also identified novel changes caused by ethanol and LPS. For
example, previous studies have shown an association between vitronectin
accumulation and HF/end‐stage liver disease.(119, 120) The results of the
current study suggest that more subtle changes in vitronectin abundance occur
before the onset of fibrosis and hepatic decompensation. Ethanol exposure also
resulted in the detection of galectin‐1. Galectin‐1 is a glycosaminoglycan‐binding
lectin associated with cell proliferation and adhesion through modulation of
glycoprotein cross‐linking. Galectin‐1 may also play a role in hepatic
inflammation and fibrinogenesis.(134) These data suggest that ethanol and/or
LPS likely contribute to a multitude of changes in the ECM composition, many of
which have not yet been fully investigated.
Changes in abundance of protease and protease inhibitors can also
contribute to inflammatory liver injury and fibrogenesis. In the current study,
several ECM‐associated proteases were increased in response to stress,
including plasmin(ogen), antithrombin III, dipeptidyl peptidase, and alpha‐1‐
antitrypsin. Stress also resulted in the presence of protease inhibitors, such as
serpine B5 (maspin) and plasminogen activator inhibitor‐1 (PAI‐1). Ethanol
and/or LPS increased several other proteases and protease inhibitors that may
be critical for ECM homeostasis (e.g., transthyretin, phosphatidylethanolamin‐
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binding protein‐1 [PEBP1], and serine protease inhibitor A2K). These data
support the notion that transitional remodeling of the hepatic matrisome is
bidirectional, driven by both increased secretion of matrix proteins as well as
altered ECM degradation.
As mentioned above, ethanol is well known to synergize liver damage caused
by LPS exposure. In the current study, the combination of ethanol and LPS
resulted in unique changes to the hepatic matrisome compared to either ethanol
or LPS alone. Indeed, coexposure differentially increased fibronectin and
biglycan abundance (Fig. 3.3; Table 3.1). Fibronectin accumulation caused by
ethanol may contribute to hepatic inflammation through stimulation of Kupffer
cells (KCs). (135) Biglycan is a small proteoglycan that was first recognized as a
structural component and signaling molecule in the ECM (136). Biglycan has
also been implicated in inflammation, (137) possibly by retaining proinflammatory
cytokines,(138) and/or by activating TLR4 signaling.(138) These data suggest
that biglycan abundance may be increased in prefibrotic stages of liver disease.
In contrast, the combination of ethanol and LPS synergistically decreased
PEBP1; this enzyme has been shown to inhibit trypsin‐like serine proteases,
including thrombin, but not trypsin or tissue‐type plasminogen activator.(139)
Multiple studies have identified PEBP1 as a critical player in metastasis (140)
and have defined it as a metastasis suppressor gene.(141) These changes
represent dynamic (and potentially unique) responses of hepatic ECM to stress
that may serve as a basis for future biomarker and/or mechanistic studies.
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Whereas it is well established that myofibroblast‐like cells (e.g., hepatic
stellate cells) are the primary source of fibrillar ECM during HF, most, if not all,
hepatic cells contribute to overall matrisome homeostasis. For example, hepatic
sinusoidal endothelial cells are almost solely responsible for the metabolism and
degradation of hyaluronic acid. Furthermore, stress causes inflammatory cells
(e.g., KCs) and hepatocytes release proteases and protease inhibitors (e.g., PAI‐
1) that can affect the ECM. Extrahepatic sources (e.g., the coagulation and
complement cascades) can also affect the hepatic matrisome. The ECM not only
serves as a physical structure, but also binds/interacts with several biomolecules
that can directly or indirectly alter responses. For example, ECM/integrin
interactions mediate rapid and dynamic responses to changes in the
environment. It is known that fibrotic ECM is known to influence cell phenotype,
inflammation, and metastasis in the liver.(142-144) The effects of the ECM
changes observed here on earlier stages of liver injury should be investigated.
In summary, the results of this work demonstrate that the hepatic matrisome
responds dynamically to both chronic (ethanol) and acute (LPS) stresses,
preceding more‐dramatic fibrotic changes to the liver. It is likely that these
transitional changes to the hepatic ECM contribute to the pathological responses
to these stresses. It is also interesting that several ECM proteins responded
similarly to both stresses, suggesting a shared mechanism in both models.
Protein changes that were unique to either ethanol or LPS exposure alone (or
their combination) also represent potential new biomarkers or targets. These
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results therefore serve as a foundation for future analyses in models of liver
disease.

102

CHAPTER IV

NOVEL BIOMARKERS IN ALCOHOLIC HEPATITIS: ANALYSIS OF THE
PLASMA PEPTIDOME/DEGRADOME

A. Introduction
AH is an acute sequela of alcoholic liver disease with a high mortality rate
of 30-50% at 3 months and 40% at 6 months.(72, 73) AH is characterized by
jaundice and liver failure.(145) AH occurs in patients with heavy chronic alcohol
consumption (80-100 g per day) and severe ASH with or without advanced
fibrosis and/or cirrhosis.(145, 146) AH can be the first manifestation of clinically
silent ALD or an exacerbation of pre-existing cirrhosis.(145)
Accurately predicting AH patient outcome is important for clinical decisionmaking. For example, AH patients with higher risk are better candidates for
corticosteroid treatment, and patients with lower risk could be candidates for
long-term clinical studies.(72, 145) While identifying AH patients at risk of liver
inflammatory injury and failure is important, it is also difficult. Currently, the best
approach for predicting outcome is combining static scores, such as the modified
Maddrey’s discriminant-function, MELD, ABIC (Age, Bilirubin, INR and
Creatinine) and/or Glasgow with the dynamic Lille scoring system.(147) These
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clinical scores are useful for predicting outcome in patients with severe disease,
but are more limited in predicting outcome in patients with moderate AH.(84)
Our group recently demonstrated significant ECM remodeling during
inflammatory liver injury (93). During such remodeling, peptide fragments of the
degraded ECM increase in biologic fluids (e.g., plasma) (58). Peptidomic analysis
of the degraded ECM (i.e., ‘degradome’) is a useful diagnostic/prognostic tool in
metastatic cancers and other diseases of ECM remodeling (58).
It was hypothesized that the severe inflammatory liver injury caused by AH
would yield a unique degradome profile in human patient plasma, and that ECM
peptides would change between patient groups. The goals of this work are
twofold: 1.) to identify novel candidate biomarkers for AH, and 2.) to develop new
mechanistic hypotheses by predicting proteases that generated the observed
degradome.

B. Experimental procedures
1. Study participants and inclusion criteria
AH patients, AUD patients, and healthy volunteers were enrolled in the study
as described in Chapter II.

2. Study paradigm
Relevant clinical data were collected as described in Chapter II. As provided
in the workflow scheme in Figure 4.1, this study was designed to analyze plasma
peptides for comparison between healthy volunteers, AUD patients (“mild”, with
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or without liver injury), patients with moderate AH, and patients with severe AH
for potential associations between parameters.

3. Plasma collection
Plasma was collected from study participants as described in Chapter II.

4. Plasma peptide purification
Plasma peptide purification was optimized and carried out as described in
Chapter II.

5. Liquid chromatography and tandem mass spectrometry
LC-MS/MS analysis was carried out as described in Chapter II

6. Data analysis
Peptidomic data analysis was performed as described in Chapter II.

7. Statistical analysis
Peptidomic data were log2 transformed prior to statistical analysis. Statistical
analysis was performed as described in Chapter II.
C. Results
1. Patient demographics
A total of 114 participants including healthy volunteers (n=7) and AH (n=107)
patients stratified by MELD scores into three categories were studied. AH
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Figure 4.1: Scheme of peptidomic workflow.
Plasma samples were handled randomly in balanced proportions between
groups to avoid systematic bias. Plasma peptides were purified by TCA
precipitation and underwent LC-MS/MS analysis with de novo spectrum
assignment. We identified peptides significantly changing between MELD
groups.
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patients with AUDs having a MELD score less than 12 were assigned to the mild
category (n=45), patients having a MELD score between 12 and 19 were
assigned to the moderate category (n=25), and patients having a MELD score
greater than 19 were assigned to the severe category (n=37). The AUD/mild
category was further subdivided into patients without liver injury (ALT<40, “MildA”, n= 14) with liver injury (ALT≥40, “Mild-B”, n=31). A variety of clinical data was
gathered for these patients, including transaminases, alkaline phosphatase, and
total bilirubin. Table 4.1 shows a list of demographics and clinical data for the
healthy, AUD (‘mild’), moderate AH, and severe AH participants.

2. Plasma peptides change between MELD groups
To visualize differences in the patients based on the peptidomic data, PCA
was carried out (Fig. 4.2). Principal components 1 and 2 accounted for 51.59%
and 5.14% of the variability between the five peptidome cohorts. PCA1 was the
component explaining the largest set of variability (51.59%) in the data as could
be attributed to the differences between Mild-A + Mild-B versus Moderate +
Severe peptidomes. PCA2 was the component explaining the second largest set
of variability in the data (5.14%). This component was 10-fold less than PCA1
and could be attributed to the differences between Healthy Controls versus AH
(Mild-A + Mild-B + Moderate + Severe). The hierarchical clustering of the
peptidome as grouped patient samples by similar MELD scores (Healthy Control;
Mild-A and Mild-B; Moderate and Severe) identified three primary clusters of
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Table 4.1: Patient demographics

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

Age
Healthy volunteer
7
0
28.14
26.00
4.74
25.00
38.00

Mild-A*
14
0
40.02
37.30
11.74
25.30
62.90

Mild-B**
31
0
44.05
44.00
10.26
23.19
67.00

Moderate***
25
2
49.83
51.00
9.97
31.00
63.00

Severe***
37
0
48.92
50.00
10.67
27.00
66.00

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

AST (SGOT) (IU/L)
Healthy volunteer
7
2
24.40
25.00
2.88
21.00
28.00

Mild-ANS
14
0
36.00
26.00
20.00
17.00
87.00

Mild-B**
31
0
131.55
96.00
103.71
21.00
388.00

Moderate**
25
2
135.30
114.00
77.66
18.00
347.00

Severe**
37
0
141.08
122.00
71.26
41.00
370.00

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

ALT (SGPT) (IU/L)
Healthy volunteer
7
2
20.40
17.00
5.18
16.00
27.00

Mild-ANS
14
0
27.57
27.00
8.05
14.00
39.00

Mild-B****
31
0
97.68
83.00
59.31
40.00
312.00

ModerateNS
25
2
59.78
46.00
45.63
15.00
194.00

SevereNS
37
0
48.95
40.00
30.11
12.00
159.00

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

Alkaline
phosphatase
(IU/L)
Healthy volunteer
7
2
48.80
54.00
10.92
37.00
59.00

Mild-ANS
14
0
68.50
64.50
27.05
44.00
147.00

Mild-BNS
31
0
93.52
91.00
25.62
56.00
150.00

Moderate***
25
2
175.91
147.00
109.32
41.00
483.00

Severe***
37
0
180.65
157.00
83.90
72.00
443.00

109

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

Bilirubin (mg/dL)
Healthy volunteer
7
2
0.52
0.50
0.13
0.40
0.70

Mild-ANS
14
0
0.86
0.60
0.93
0.20
4.00

Mild-BNS
31
0
0.74
0.60
0.57
0.20
2.60

Moderate*
25
2
7.22
5.10
7.66
0.60
35.00

Severe****
37
0
18.31
18.20
7.69
4.70
34.20

Groups
# Samples
# Missing
Mean
Median
Std. Dev.
Min.
Max.

Albumin (g/L)
Healthy volunteer
7
2
4.06
4.20
0.31
3.60
4.40

Mild-ANS
14
0
4.03
4.10
0.34
3.20
4.50

Mild-BNS
31
0
4.17
4.20
0.50
2.60
5.20

Moderate****
25
2
2.77
2.80
0.68
1.70
4.50

Severe****
37
0
2.51
2.40
0.46
1.60
3.50

Sex
Groups
# Samples
# Missing
# Males
# Females

Healthy volunteer
7
0
1
6

Mild-AND
14
0
7
7

Mild-BND
31
0
26
5

ModerateND
25
2
15
8

SevereND
37
0
24
13

Healthy volunteer
7
0
7
0

Mild-AND
14
0
14
0

Mild-BND
31
0
30
1

ModerateND
25
3
11
11

SevereND
37
0
5
25

0

0

0

0

7

Healthy volunteer
7
0
5

Mild-AND
14
1
12

Mild-BND
31
2
26

ModerateND
25
11
1

SevereND
37
10
0

Ascites
Groups
# Samples
# Missing
# None
#
Mild/Moderate
# Severe
Plasma color
Groups
# Samples
# Missing
# Light yellow
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# Light
orange
# Light red
# Dark yellow
# Orange
# Red orange
# Red

0

0

2

0

0

0
0
2
0
0

0
0
0
0
1

1
0
0
0
0

0
12
1
0
0

0
23
3
1
0

ND- not determined
NS- not significant
*p<0.05
**p<0.01
***p<0.001
****p<0.0001
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Figure 4.2: Multivariate analysis of the plasma peptidome using principal
component analysis biplots and heat maps with hierarchical clustering.
Patient differences for different AH severity groups based on peptidome were
visualized using (Fig 5A) PCA and heat maps with hierarchical clustering (Fig
5B). PCA was carried out for significantly changed peptides (BH corrected pvalue <0.05) using a linear mixed model approach. “Age” and “Sex” were
considered fixed variables, and “Flight” and iRT1-11 peptide standards were
considered random variables.
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A.

B.

Healthy Mild-A Mild-B Moderate Severe
volunteer
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peptides . The first cluster was interpreted as peptide abundances in order of
HC > Mild-A = Mild-B > Moderate = Severe. The second cluster was interpreted
as peptides abundances in order of Mild-A = Mild-B > HC = Moderate = Severe.
The third cluster was interpreted as peptide abundances in order of Moderate =
Severe > HC > Mild-A = Mild-B; thus each disease severity stage yielded a
unique peptidome pattern (Figure 4.3).
Linear discriminate modeling of the cohort peptide abundances following
adjustment for age, sex, iRT internal standards, and sample analysis flight
identified 12-497 differentially regulated peptides (Table 4.2). These pairwise
differences were in agreement with PCA loading comparisons demonstrating
very small numbers of significantly regulated peptides between Mild-A and Mild-B
while large differences between HC and each AH cohort member. Individual
pairwise comparisons by volcano plots were used to illustrate peptides that are
differentially abundant by both statistical significance and fold change (Figure
4.3).

3. ECM peptides change between MELD groups
To address the working hypothesis that surrogate markers of AH would be
associated with altered matrisome metabolism, the regulated peptides (q-value
<0.05) identified from the iterative pairwise comparisons of Healthy Control (HC)
versus AH cohort (Mild-A, Mild-B, Moderate and Severe) as well as the
comparisons of Mild-A to Mild-B and of Moderate to Severe were assembled into
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Table 4.2: Pairwise comparisons of peptidomes.

# Differentially
expressed

# Up
regulated

# Down
regulated

Healthy volunteer vs.
Mild-A

497

130

301

Healthy volunteer vs.
Mild-B

392

112

226

Healthy volunteer vs.
Moderate

207

32

152

Healthy volunteer vs.
Severe

344

109

205

Mild-A vs Mild-B

12

1

1

Moderate vs. Severe

94

37

11

Comparison
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Figure 4.3: Pairwise comparison of the peptidomes of patients with
different AH severity by volcano plots.
Peptide abundance differences were plotted as log2 of the fold-change versus –
log10 BH-corrected p-value. Peptides with BH-corrected p-value < 0.05 and
log2FC ≥ 1 were considered significantly upregulated, and peptides with BHcorrected p-value <0.05 and log2FC ≤ -1 were considered significantly
downregulated. The Tukey's HSD test was used for all pairwise comparisons.
Pairwise comparisons were illustrated for the major comparators of: A. Healthy
vs. Mild-A, B. Healthy vs. Mild-B, C. Healthy vs. Moderate, D. Healthy vs.
Severe, E. Mild-A vs Mild-B, F. Moderate vs. Severe.

116

A

B

C

D

E

F

117

a spreadsheet. The gene names associated with each differentially regulated
peptide were submitted for annotation by matrisome category and division using
the matrix-annotator tool at the MIT Matrisome project website
(http://matrisomeproject.mit.edu/analytical-tools/matrisome-annotator/). These
gene names were annotated by the matrisome-annotator tool as a component of
the core matrisome (collagen, ECM glycoprotein, proteoglycan) or the matrisome
associated compartment (ECM regulators, ECM-affiliated proteins, secreted
factors). The regulated ECM peptidome (Table 4.3) by absolute numbers were
ranked in the following order: (HC versus Mild-A or Mild-B) >>> (HC versus
Moderate or Severe) >>> (Moderate versus Severe) or (Mild-A versus Mild-B).
These data suggest that the plasma peptidome may be able to discretely
differentiate HC versus Mild AH and Moderate versus Severe AH.
The regulated ECM peptides for the HC versus AH cohorts (Mild-A, Mild-B,
Moderate, and Severe) were compared by Venn Diagram (Fig. 4.4 inset) and
regulated peptides to all four comparisons were identified. The annotation of
these gene names by matrisome-annotator identified 4 ECM peptides out of 101.
These four peptides included: one peptide derived from collagen (I) alpha 2
labeled as COL1A2-394 with the sequence
612SGP(OH)PGPDGNKGEP(OH)GVVGAVGTAGP635,

two peptides from

fibrinogen alpha chain FGA-649 (426REYHTEKLVTSKGDKEL442), FGA-1238
(581KQFTSSTSY589), one peptide SRGN-392 from serglycin
(135SLDRNLPSDSQDLG148), and one peptide from kininogen-1 (KNG1-123),
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Table 4.3: ECM-Matrisome Annotation for Pairwise Regulated Peptides.

Peptidome

Total Peptides
Non-ECM
ECM Peptides
Core Matrisome
Peptides
-Collagens
-ECM Glycoproteins
-Proteoglycans
Matrisome-associated
-ECM Regulators
-ECM-affiliated
Proteins
-Secreted Factors

Healthy
Control
versus
Mild-A

Health
y
Control
versus
MildA2

Healthy
Control
versus
Moderat
e

Health
y
Control
versus
Severe

Mild-A
versu
s
Mild-B

Moderat
e
versus
Severe

497

392

207

344

12

94

9 (75)

23 (24)

3 (25)

71 (76)

2 (17)

67 (71)

246 (49)
251 (45)
226 (45)

207
(53)
185
(47)
169
(43)

172 (83)
35 (17)
31 (15)

204
(59)
140
(41)
127
(37)

104

59

21

81

0

52

118

107

6

39

2

14

4

3

4

7

0

1

25 (5)

16 (4)

4 (2)

13 (4)

1 (8)

4 (4)

24

16

4

11

1

4

1

0

0

1

0

0

0

0

0

1

0

0

(percentage
)
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Figure 4.4: Regulated peptides common to HC to AH pairwise comparisons
include ECM peptides.

Regulated peptides were identified using data from volcano plots of HC vs. MildA, HC vs. Mild-B, HC vs. Moderate, and HC vs. Severe were compared by Venn
diagram analysis (inset). Peptides common to all comparisons (n=101) were
annotated for GO and the relative fold difference of the HC to AH-cohort plotted
for all ECM peptides.
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245RPPGFSP251

(also known as bradykinin 1-7). As illustrated in Figure 4.4, two

peptides (COL1A2-394, SRGN-392, and KNG1-123) increased with AH severity,
one peptide (FGA-1238) decreased with AH severity and two peptides (FGA-649
and SRGN-392) were reduced across all AH cohorts and did not change with AH
severity. These data demonstrate the response of select matrisome
compartments across the AH spectrum.

D. Discussion
AH is a diagnosis of acute hepatic inflammation and liver failure based on
AST, AST/ALT, serum bilirubin, INR, neutrophilia, ascites, and history of
AUD.(72) AH has a 3-month mortality rate of 30-50%.(73) Both AH diagnosis
and prognosis could be impacted by the development of more sensitive and
specific biomarkers. Our group previously demonstrated that inflammatory stress
causes the hepatic ECM to undergo dynamic transitional remodeling.(93) Others
have shown that ECM remodeling causes degradation products to be secreted
into blood and that analysis of these peptides (i.e. the ECM degradome) is a
useful prognostic tool in diseases that involve ECM remodeling.(58, 59)
Therefore, the work in this pilot study aimed to test the hypothesis that the
plasma ECM degradome changes with AH severity.
To this end, peptides were purified from AH patient plasma and analyzed
using LC-MS/MS. Internal standards (non-human peptides, iRT, Biognosis USA,
Beverly, MA) spiked into samples enabled normalizing of day-to-day instrument
performance during the statistical modeling using linear mixed model approach.
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Patients were divided into groups based on AH severity (MELD score) and the
changes in the peptidome patterns across groups were examined with
multivariate analyses, considering age and sex as fixed variables, and flight and
the 11 peptide standards as random variables. The PCA approach to data
analysis is based on data reduction and collapses all data points within a sample
into a single x,y coordinate. This approach allowed for an unbiased self-sorting at
the patient level, not the discrete peptide level, based on the intrinsic nature of
the data. These data demonstrated that differences in the peptidome can
separate patients by AH severity group. Principal component 1, which accounted
for 51.59% of variability in the data, generally separated Mild-A and Mild B from
Moderate and Severe, with the Healthy group in the middle. Principal component
2, which accounted for 5.14% of variability in the data, appeared to separate
healthy patients from all AH patients. PCA showed little difference between MildA and Mild-B or between Moderate and Severe. The subsequent multivariate
approach for modeling the peptidome data was hierarchical clustering with heap
maps grouping the relative peptide abundances into unique patterns in the
peptidome between AH severity groups. The hierarchical clustering of the
complete dataset identified three strong groupings of peptide abundance patterns
that reflected combinations of (A) increased peptide levels in healthy controls, (B)
increased peptide levels in Moderate + Severe and (C) increased peptide levels
in Mild-A + Mild-B AH cohorts. These data supported the justification to conduct
pair-wise comparisons of the mean peptide differences between HC and AH
cohorts. Post-hoc filtering of the differentially abundant peptides identified strong
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relative abundance changes in ECM peptides with strong differences noted in the
collagen and fibrinogen peptides. Consistent with the multivariate analysis, the
largest changes in the peptidome were observed between mild vs. healthy and
severe vs. healthy. While each pairwise comparison is heavily dominated by
ECM fragments, the regulated peptides common to all HC to AH comparisons
only contained 5 ECM peptides out of a possible 101. While these pilot data
provide strong evidence that altered ECM turnover is associated with the AH
spectrum additional research is required to confirm these findings.
While the sample handling, sample analysis and statistical modeling
integrated methods for sample handling randomization, inclusion of internal
standards and statistical modeling to account for random or fixed effect variables
there are still several limitations to these studies that should be noted. The
balance of HC to AH cohort is imbalances in “n” values and this may be
insufficient to adequately power the study. Additionally, the potential for a
“clinical site effect” is present. The HC plasma samples were recruited at the
University of Louisville. The Mild-A and Mild-B plasma samples were recruited at
the NIH-NIAAA. The Moderate and Severe plasma samples were recruited at
the University of Louisville, the University of Massachusetts Medical School, the
University of Texas-Southwestern and the Cleveland Clinic. Therefore, the
potential for a “clinical site effect” is present. Despite these study limitations the
statistical modeling and informatics filtering of the peptidomics data supports the
hypothesis that the ECM plasma degradome is associated with the AH spectrum.
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These patterns of select peptidome “features” can be investigated further in
future studies as biomarkers for AH severity and outcome.
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CHAPTER V

CHRONIC MODERATE ALCOHOL CONSUMPTION INFLUENCES RENAL
CORTICAL OXIDANT RESPONSE PATHWAYS

A. Introduction
Ethanol (EtOH) is arguably the most common substance voluntarily
consumed at toxic doses by humans. Pharmacologically relevant concentrations
of EtOH affect multiple organs,(148, 149) and EtOH consumption is a known risk
factor in over 200 health conditions (9). Despite this knowledge, the ability to
reverse EtOH-induced organ damage or predict at-risk individuals for EtOHinduced organ damage is limited even in well-known target organs (e.g. the liver)
(150). In contrast to the liver, it is unclear if the kidney is a direct target of EtOH
toxicity. Heavy EtOH consumption is well recognized to be associated with
enhanced risk for renal failure secondary to hepatic cirrhosis, a phenomenon
known as hepatorenal syndrome (HRS) (151). Renal failure associated with HRS
is a complication in 14.4% of AH patients having MELD scores ≥22 (152). The
widespread view that this renal failure is strictly secondary to hepatic cirrhosis
with no role for direct EtOH nephrotoxicity may largely be an artifact of clinical
charting, as was the case for alcoholic pancreatic damage (153). Moderate
EtOH consumption is, however, absent from listed risk factors for chronic kidney
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disease (154), and connections between alcohol use disorders and kidney
damage are controversial (155). Studies on moderate EtOH consumption have
shown EtOH to be (1) inversely associated with development or progression of
chronic kidney disease (85, 95, 156, 157) and (2) associated with improved
outcomes in renal transplant patient populations (158, 159). However, these
studies were not specifically designed to address the question as to whether or
not EtOH consumption damages the kidneys, and a mechanistic explanation for
these observations has not been explored. Overall, a more in-depth investigation
is justified to discern both the direct and indirect effects of EtOH on the kidney.
Rodent studies have identified detrimental effects of EtOH to kidney at the
tissue and subcellular, including increased tissue markers of oxidative damage
and myeloperoxidase expression in rats (87) and increased Cyp2e1
induction(88), and mitochondrial protein hyper-acetylation in mice (86). These
investigations have been driven by the hypothesis that the effect of EtOH on the
kidneys mirrors its effects on the liver. Confirmation of these parallel mechanisms
between these two organs may be due to similarities in expression of EtOH
metabolizing enzymes Cat and Cyp2e1. However, while the liver and kidney are
the major organs for EtOH detoxification, significant differences in structure,
function, and parenchymal composition exist.
We used discovery-based proteomic and transcriptomic approaches to study
the effects of EtOH on the renal cortex and secondarily the effects of EtOH preexposure on the response (4h and 24h) to LPS (10mg/kg i.p.). Integrated IPA
studies demonstrated significant EtOH-alone effects on multiple canonical
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signaling pathways including decreased activation of the Nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) and increased activation of the aryl
hydrocarbon receptor (Ahr) oxidative stress responses pathways. These studies
suggested an EtOH-dependent, selective dysregulation of cortical oxidant
response pathways.

B. Experimental procedures
1. Animals and exposures
Mice were exposed to chronic ethanol and/or LPS as described in Chapter II.
Mice were exposed to chronic ethanol and/or ethanol binge as described in
Chapter II.

2. Histology and immunohistochemistry
Renal cortex tissue was stained with PAS as described in Chapter II. IHC for
Mpo and Cat was conducted on renal cortex tissue as described in Chapter II.

4. Blood urea nitrogen analysis
BUN in mouse plasma was determined using a standard kit as described in
Chapter II.

5. Proteomic sample handling
3 control mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice
were used for the renal cortex proteomic analysis. Proteins were extracted from
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renal cortex tissue, digested, labeled, and prepared for LC-MS/MS analysis as
described in Chapter II.

6. Liquid chromatography and tandem mass spectrometry
1D-LC-MS/MS analysis and subsequent data analysis were carried out as
described in Chapter II

7. RNA seq analysis
3 control mice, 3 ethanol mice, 3 4h LPS mice, and 3 ethanol+4h LPS mice
were used for the renal cortex transcriptomic analysis. The same mice were
used for the renal cortex proteomics and transcriptomics, except for 1 4h LPS
mouse and 1 ethanol+4h LPS mouse that were different. RNA was isolated from
renal cortex sections and RNA Seq analysis was carried out as described in
Chapter II. RNA Seq data were analyzed as described in Chapter II.

8. Multivariate analysis of proteomic and transcriptomic data
Multivariate analysis of proteomic and transcriptomic data was completed as
described in Chapter II.

9. Immunoblot analysis
Western blot analysis was carried out on protein extracted from renal cortex
tissue as described in Chapter II. Primary antibodies against Nqo1, Sod1, Sod2,
Gclc, and Cat were used.
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10. Statistical analyses
Statistical analyses of proteomic and transcriptomic data were carried out as
described in Chapter II.

C. Results
1. Ethanol, LPS, and the combination increase blood urea nitrogen
The Lieber-DeCarli model (Fig. 5.1A) of chronic moderate EtOH consumption
was used to examine the effects of EtOH ± LPS on the kidneys of male mice.
This is an established model that causes early alcohol-induced liver injury and
sensitizes the liver to a subsequent inflammatory insult, such as LPS.(93).
Ethanol consumption caused a small but significant increase in BUN levels
(p<0.05) in mice in the absence of an LPS challenge (Fig. 5.1B). LPS injection
significantly increased BUN levels (p<0.005) 24h after injection; ethanol exposure
did not significantly alter the increase in BUN caused by LPS administration.

2. Ethanol alone contributes little-to-no morphological changes to
mouse renal cortex
Analysis Hematoxylin and Eosin- (H&E, not shown) and PAS-stained (Fig.
5.2) tissue sections identified mild proximal tubular brush border loss with LPS
and increased infiltration of polymorphonuclear leukocytes (PMNs, as noted by
yellow arrows). However, little-to-no obvious histologic differences were detected
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Figure 5.1: Effects of chronic moderate EtOH feeding and low dose
(10mg/kg intra-peritoneal (i.p.) lipopolysaccharide (LPS) on blood urea
nitrogen (BUN).
(A) To model chronic moderate EtOH consumption the Lieber DeCarli diet model
of a four week escalation followed by a two week hold at 6% EtOH in the liquid
diet was used. Control animals received a isocaloric substitute of maltose-dextrin
in the liquid diet. A LPS (10mg/kg) LPS or saline injection given i.p. either 4h or
24h prior to sacrifice. (B) Baseline differences in BUN were observed with EtOH
feeding as well as an LPS effect at 24h. Statistical differences were determined
using students t-test or two-way ANOVA, *p≤0.05, **p≤0.005.
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Figure 5.2: Mild effects of EtOH and/or LPS on renal architecture.
Histologic evaluation by periodic acid-shiff (PAS) stain (100x) demonstrates
unremarkable effects on renal parenchymal architecture of control (left column,
n=3) versus EtOH fed (right column, n=3) animals. Following low-dose
(10mg/kg) i.p. LPS renal cortical sections demonstrate low to moderate levels of
tubular dilation, vacuolization, brush border loss and PMN infiltration at 4h
(middle row) and 24h (bottom row). Glomerular infiltration by
polymorphonucleated cells is noted by yellow arrows (→).
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EtOH

in kidneys from mice exposed to EtOH versus control or EtOH + LPS versus LPS
alone, suggesting at the gross level there was no need for tissue scoring of
kidney histology.

3. Ethanol attenuates LPS-induced cortical recruitment of MPO-positive
cells
Although gross histology was unaffected by exposure regimen, the PAS stain
demonstrated that LPS exposure increased the number of infiltrating neutrophils
and caused brush border loss both 4 and 24h after challenge in the EtOH and
control cohorts. Based on quantitative IHC, control and EtOH-fed mouse kidneys
were similar and unremarkably different for Mpo staining (Fig. 5.3). LPS induced
a strong, significant recruitment of Mpo-positive cells into the cortex. Moreover,
EtOH significantly attenuated the recruitment of Mpo-positive cells caused by
LPS at 4h but not 24h post-injection (Fig. 5.3).

4. Ethanol and LPS each cause unique protein abundance patterns.
Proteomic analysis of TMT 10-plex labeled cortical digests (Fig. 5.4A)
resulted in identification of over 2,400 proteins (Fig. 5.4B) by two or more
peptides. Chronic, moderate EtOH consumption increased the abundance of 22
proteins and decreased the abundance of 70 proteins (Fig. 5.4C). Significant
protein abundance changes in the LPS compared to control animals were
greatest at 24h (108 increased, 10 decreased) compared to 4h-post LPS
challenge (43 increased and 19 decreased) (Fig. 5.4D-E).
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Figure 5.3: LPS induced infiltration of myeloperoxidase (MPO) positive
cells into the renal parenchyma.
(A) Infiltration of MPO positive cells was quantified by IHC staining and counting
of MPO-positive cells (40x) in glomerular (→) and tubular (→) compartments
(33±4 visual fields per kidney section). (B) Infiltration was significantly increased
at both 4h (n=3) and 24h after LPS (n=3), compared to baseline (n=3). There
was significant difference between control (n=3) and EtOH fed animals (n=3) at
4h post low dose LPS i.p. challenge. Statistical differences were determined
using students t-test or two-way ANOVA, *p≤0.01, **p≤0.005, @p≤0.0001.
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Figure 5.4: Workflow and characterization of the global effect of EtOH and
LPS on the cortical proteome.
Using a TMT workflow (5.4A) the renal proteomic dataset included 2,487 proteins
(>98% at ≥2-peptide level, (5.4B) detected with high confidence. Differences of
relative abundance are shown as Log2 fold change (FC) and are evaluated in
volcano plots (5.4C-G) with a FC >1.2 and corrected ANOVA p-value<0.05
considered significant. As a primary hit, the effects of EtOH and LPS are
comparable in magnitude. This time dependent effect was maintained (5.4F-G)
with the two-hit comparison of EtOH on an LPS background (EtOH+LPS versus
LPS) with smaller differences observed by log2 FC (EtOH+4hLPS to 4hLPS)
compared to log2FC (EtOH+24hLPS to 24hLPS).
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value) <0.05) trends in protein abundance fold-changes (Log2FC>0.5 or
Log2FC<-0.5) with larger fold changes between two or more conditions. A four
protein grouping (Ehhadh, Acad11, Sqstm1, and Hnrnpc) had diminished
abundance with EtOH versus control (Fig. 5.5A, dotted box) but the differences
were normalized at 4h- and 24h-post LPS. A second grouping of ribosomal
proteins (Rpl6, Rpl8, Rpl13a, and Rps15) had increased abundance in EtOH-fed
animals on a background of 24h LPS (Fig. 5.5B, dotted box).

5. RNA seq data support proteomic data for LPS effect.
To study the early two-hit effects of EtOH ± LPS, the RNA were isolated from
EtOH, control, 4h LPS and EtOH+4h LPS animals only. The RNA integrity
number (RIN) values for RNA isolated from mouse kidneys averaged 7.8 ± 0.5.
Following ribosomal depletion, RNA library preparation and high throughput
sequencing, a total of 47,719 transcripts were observed including 24,405
detected in all samples. Of 47,719 detected transcripts, EtOH increased the
expression of 88 and decreased the expression of 99 (Fig. 5.6D/Table 5.1A).
LPS increased the expression of 1,468 and decreased the expression of 911
transcripts (Fig. 5.6E/Table 5.1A). Hence, 4h LPS, compared to EtOH, induced
approximately a 10-fold increase of differentially abundant transcripts relative to
the control animals (Fig. 5.6E-G). As shown in Table 1, EtOH significantly (q ≤
0.05; Log2FC≥1) altered the expression of six (6) transcripts apparently
independent of LPS.
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Figure 5.5: Quantitative cluster analysis reveals EtOH-regulated protein
clusters.
Log2 FC values are plotted relative to the pooled internal standard reporter ions.
(A) EtOH-dependent, LPS-independent protein abundance changes. Significant
differences (q-value <0.05) were observed for a protein cluster in control versus
EtOH (black dotted boxes). (B) EtOH-dependent and late (24h) low dose LPS
protein abundance changes of ribosomal-related gene product cluster.
Significant differences (q-value <0.05) were observed for LPS 24h versus EtOH
+LPS 24h (black dotted boxes).
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6. Ethanol alone downregulates Nrf2-mediated oxidative stress
response pathways at the protein level and transcript level.
A multivariate comparison by IPA of the top-20 canonical signaling pathways
for the proteome and transcriptome by single-hit (EtOH compared to control,
4hLPS compared to control) and two-hit comparisons (EtOH + 4h LPS compared
to 4h LPS; EtOH +4h LPS compared to EtOH) are shown in Fig. 5.5A. The
effects of EtOH feeding ± LPS exposure on signaling pathways (Fig 5.5A) or
individual protein abundance levels (Fig 5.5B) are illustrated as heat maps.
Heat-map colors are assigned dichotomously to illustrate activation (positive Zscore, red/orange) or inactivation (negative Z-score, green/blue) based on the
Log2 relative abundance changes for proteins or transcripts within the pathway
as previously discribed.(160, 161) Six overlapping canonical pathways (noted by
asterisks) for EtOH alone include effects on cell-cell interactions, oxidant stress
response, actin reorganization, protein unfolding stress response and protein
translation.
In the EtOH vs. control comparison for both the proteomic and
transcriptomic analyses, Ahr signaling had a positive z-score (i.e. overall pathway
activation) largely due to decreased abundance of heat shock protein 90-α and –
ß proteins, increased abundances Ahr-targets Nqo1, Aldh isoforms and Gst
enzymes. Nrf2-mediated oxidative stress response canonical pathway had a
negative z score (i.e. overall pathway deactivation, Fig. 5.7A-B) due to large
decreases in Nrf2 targets such as Sod1, Sqstm1/p62, and Gclc. LPS caused
overall strong positive z-scores for the acute phase response signaling pathway
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Figure 5.6: Workflow and characterization of the EtOH and 4h LPS
regulated transcriptomes.
Of 47,719 detected transcripts (36,571 in Venn Diagrams) after filtering for
corrected p-value (Benjamini-Hochberg q-value <0.05), (D) EtOH increased the
expression of 88 (red points) and decreased the expression of 99 (green points).
(E) LPS increased the expression of 1,468 (red points) and decreased the
expression of 911 (green points) transcripts. (F) EtOH on a background of 4h
LPS increased the expression of 79 (red points) and decreased the expression of
68 (green points) transcripts.
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Table 5.1: Effects of EtOH and LPS on differentially regulated cortical RNA
transcripts, differentially regulated genes, and one-hit/two-hit associated
Top-5 Gene Ontology (GO) terms.
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Transcriptional Responses

Treatment

Comparator

EtOH
4h LPS
EtOH+4h LPS
EtOH + 4h LPS

Differentially Expressed Genes (DEGs)
Multiple Comparison
Correction

Relative Fold-Change
Filtered

p ≤ 0.05 q ≤ 0.05

p ≤ 0.05 q ≤ 0.05; logFC≥1

187 (88↑, 99↓)
2379 (1468↑, 911↓)
2695 (1538↑, 1157↓)
147 (79↑, 68↓)

66 (22↑, 44↓)
1814 (1141↑, 673↓)
1842 (1114↑, 728↓)
135 (68↑, 67↓)

Control
Control
EtOH
4hLPS

DEG Expression Regulation Trends (q ≤ 0.05; logFC≥1)
mRNA Expression Changes by EtOH diet independent of 4h LPS exposure
Kynu ↑
Slc7a12a↑

Cntnap5↓
Cyp4a12a↓

Gm6300↓
Kif20b↓

mRNA Expression Changes by 4h LPS exposure independent of EtOH diet
Ifit1 ↑
Ifit2↑
Saa2↑

Lcn2↑
Camp ↑
Cxcl1↑

Cxcl10↑
Gm28347↑
Mx1↑

Slfn4↑
Trem1↑

Bsnd↓
Cd300lg↓
Cldn15↓

Clec14a↓
Cyp26b1↓
Exoc3l2↓

Myct1↓
Rasgrp3↓
Slc9a3r2↓

Sox17↓

Regulated Transcripts: Treatment versus Control (One-hit)
Treatment

EtOH

4h LPS

GO Term Description
response to interferon-gamma
skeletal muscle tissue development
innate immune response
regulation of body fluid levels
skeletal muscle organ development
innate immune response*
response to cytokine*
regulation of cytokine production*
defense response to other organism*
positive regulation of cytokine production

Genes
2
3
5
4
3
146
130
128
123
97

q-value
0.011
0.012
0.012
0.014
0.014
8.43E-50
4.94E-36
1.96E-34
4.76E-34
4.24E-31

Regulated Transcripts: Treatment versus [EtOH + 4h LPS] (Two-hit)
Treatment

EtOH

4h LPS

GO Term Description
innate immune response*
response to cytokine*
defense response to other organism*
regulation of cytokine production*
cellular response to cytokine stimulus
positive regulation of smooth muscle cell proliferation
positive regulation of cell migration
positive regulation of cell motility
wound healing
positive regulation of cellular component movement
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Genes
149
140
122
126
107
6
11
11
10
11

q-value
4.34E-51
6.71E-42
1.22E-32
2.18E-32
1.08E-29
6.24E-06
1.42E-05
1.91E-05
2.16E-05
2.37E-05

and the LXR/RXR activation pathway, whether or not mice were fed an EtOH
diet.

7. Effects of ethanol and LPS on catalase abundance.
Cat IB analysis confirmed proteomic findings, demonstrating a significant (2way ANOVA, *p-value<0.05) decrease of approximately 40-50% in the renal
cortical tissue of EtOH fed mice with an insignificant LPS-effect (Fig. 5.10A-B).
Additional Cat IB analyses lysates from a chronic-plus-binge study of alcohol
feeding demonstrated similar effects on Cat abundance following 10-day EtOH
feeding or, strikingly, 9h post-EtOH gavage (Fig. 5.10C). This data suggested the
effect of EtOH on Cat abundance was not associated with the chronicity of EtOH
feeding, IB.

8. Data Sharing
Proteomic files including acquired LCMS data (.RAW), search engine files
(.mgf), and search results aggregated into a Scaffold3 (.sf3,
ProteomeSoftware.com) have been deposited with MassIVE
(http://massive.ucsd.edu/) data repository with the Center for Computational
Mass Spectrometry at the University of California, San Diego (MSV000083053)
and shared with the ProteomeXchange (www.proteomexchange.org)
(PDX011429). Experimental details for NextGen sequencing and sequencing
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Figure 5.7: | Effects of EtOH feeding on Cat abundance in the renal cortex.
Cat immunoblot analysis (A) demonstrates a significant reduction of Cat protein
with EtOH feeding (n=3) compared to control (n=3) without LPS administration
(two-way ANOVA *p-value<0.001). IHC staining (10X) for Cat (B) demonstrated
comparable EtOH-associated decreases in the cortical tissue
(cortical/juxtamedullary boundary noted by red dashed line) of LPS-naïve (n=3)
mice compared to control (n=3) and LPS-challenged mice (n=3) compared to
LPS alone (n=3). (C) Similar EtOH effects on Cat abundance were observed
using a separate more severe model of EtOH feeding (NIAAA chronic plus binge
model; control n=3, chronic EtOH n=3, EtOH gavage n=3, chronic EtOH+EtOH
gavage n=3).
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results have been deposited with the NCBI Gene Expression Omnibus (162)
(https://www.ncbi.nlm.nih.gov/geo) as the study GSE81947.

D. Discussion
Ethanol consumption is a risk factor in numerous health conditions, yet it is
still unclear if the kidney is a direct target of EtOH toxicity. Hypothesis-driven
studies on the effects of EtOH consumption on renal parenchyma are limited.
We hypothesized that chronic, moderate EtOH consumption affects the kidney
through pre- or post-translational regulation of protein abundance. Furthermore,
these modifications contribute to the kidneys response to a second acute
nephrotoxic event, such as experimental endotoxemia (163, 164). The current
study addresses the hypothesis that chronic, moderate EtOH consumption
significantly affects proteins, transcripts and canonical pathways in the kidney
and the canonical response is modified by acute experimental endotoxemia (i.e.
low dose LPS (10mg/kg) i.p.).
First, we examined the effects of EtOH and LPS on renal function and tissue
structure. EtOH significantly increased BUN, a marker of kidney injury, as in a
similar rodent model (87). LPS increased BUN (24h > 4h) in the presence or
absence of EtOH, consistent with other studies of the same dose of LPS in mice
(165). The effects of chronic, moderate EtOH consumption on the kidney at the
tissue level were largely indiscernible, as shown by PAS histology. Our data
show no significant effect of EtOH recruitment of MPO-positive cells into the
kidney unlike differing reports in the rat Lieber-DeCarli model (87). The effect of
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EtOH on LPS recruitment of MPO positive cells demonstrated a significant
decrease at 4h post i.p. challenge that was lost at 24h. It is not clear if this
difference was mitigated at the level of recruitment or clearance. However, EtOH
is known to enhance neutrophil apoptosis, which suggests that our observations
may result from increased neutrophil clearance in the EtOH fed mice (165).
Next, a discovery-based ‘omics (Fig. 2A) approach was used to unbiasedly
identify proteins, transcripts, and canonical signaling pathways affected by
chronic, moderate EtOH consumption. EtOH significantly changed 92, 14, and
109 proteins on a control, 4h LPS, and 24h LPS background, respectively. It is
known that TMT-based proteomic studies may underestimate fold-change
differences (166), and therefore these numbers may underestimate the impact of
chronic EtOH exposure on the renal proteome. Specifically, a cluster of proteins
that EtOH significantly decreased in abundance compared to control included
Ehhadh, Acad11, Sqstm1, and Hnrnpc. Ehhadh, Acad11 and Sqstm1 are
important peroxisomal proteins involved in oxidation of fatty acids and regulation
of peroxisomal matrix composition. Many other proteins changed by EtOH are
not known to play a role in EtOH-induced mechanisms in the kidney or other
organs (Supplemental Data). However, EtOH also increased the abundance of a
cluster of ribosomal proteins (Rpl6, Rpl8, Rpl13a, and Rps15) on a background
of 24h LPS. Rpl13a (ribosomal protein L13a) has previously been described as
a critical component of the interferon (IFN)-γ-activated inhibitor of translation or
‘GAIT’ system (166). The GAIT system is comprised of glutamyl-prolyl tRNA
synthetase, NS1-associated protein 1, Rpl13a, and glyceraldehyde-3-phosphate

152

dehydrogenase. The increased abundance of a critical GAIT component in the
EtOH + 24h LPS animals compared to the 24h LPS animals could contribute to
an attenuated renal IFN-γ response in the two-hit model. Further investigation
would be needed to confirm up-regulation of the GAIT system as a protective
measure for experimental endotoxemia in Lieber-DeCarli EtOH-fed animals.
The transcriptomic study identified renal transcripts and pathways affected by
EtOH and/or the early acute phase period following 4h LPS. Hierarchical
clustering of transcriptomic data demonstrates 6-7 major dendrogram arms of
robust LPS-dependent transcriptomic changes (Fig. 5.4C). For the renal
transcriptome LPS had a 10-fold larger effect on regulated transcripts (q<0.05)
and with larger fold-changes as compared to EtOH as the single hit (Table 1A).
Quantitatively, chronic EtOH consumption consistently affected a sub-set of
regulated transcripts (e.g. increased- KYNU, SLC7A12, decreased- CNTNAP5,
CYP4A12A, GM6300, and KIF20B) even on a background of LPS exposure.
The KYNU gene encodes the enzyme L-kynureninase that hydrolyzes
kynurenine into anthranilate + L-alanine. Tryptophan metabolites such as
kynurenine have been reported to inhibit aldehyde dehydrogenase (Aldh) activity
(167), and increased KYNU expression suggests an EtOH-dependent
compensatory mechanism to increase the kidneys capacity to metabolize
acetaldehyde, a toxic intermediate in the oxidation of EtOH. SLC7A12 is an Asctype cationic amino acid transporter (y+ system) and increased arginine uptake
by endothelial Asc-type cationic amino acid transporters has been shown to blunt
oxidative stress (168). GM6300 is a SLC7 pseudogene adjacent to SLC7A12 in
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the murine genome. Transcriptomic studies of 15-week old OVE26 kidneys
identified 638 genes regulated by the diabetic state. The single largest increased
(SLC7A12) and decreased (GM6300) genes by informatics analyses were
associated with endoplasmic reticulum (ER) stress (169). EtOHindependent/LPS-dependent mRNA expression (Table 5.1) changes modeled
proteomic findings for acute phase stress response (Fga, Fgb, Fgg) or interferonresponsive gene products (Ifit1, Ifit2, Saa2, and Lcn2). Unlike previous studies in
the liver and lung, LPS did not induce an EtOH-dependent synergistic increase
the acute phase response gene products PAI-1 (1, 170). Our data for significant
EtOH induction of renal CXCL1 (KC) (and CXCL10) transcript add to our prior
report in plasma, liver and lung of the Lieber-DeCarli model requiring a two hit
(EtOH + LPS) induction of KC (170). The comparison of GO terms impacted by
transcript regulation by EtOH suggested coordinated effects on a few transcripts
associated with interferon response, innate immunity response and skeletal
muscle development. Consideration of GO features for transcripts regulated by
EtOH pre-exposure on the LPS background clustered on terms for muscle cell
proliferation and cell movement. LPS as a single hit or second hit induced large
changes in transcript numbers, affecting expected GO terms: innate immune
response, cytokine response and positive regulation of cytokine production. This
more robust effect of 4h LPS on the transcriptome compared to EtOH is
unsurprising, since LPS is well known to enhance and activate gene programs of
transcription factors such as NF-κB (171, 172). Overall, the transcriptomic effect
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of EtOH is muted as compared to the proteomic effect but in some regards
parallels other murine disease models associated with ER stress.
The proteomic and transcriptomic effects of EtOH and/or LPS were integrated
using pathways analysis. The integrated data revealed that EtOH, LPS, and
EtOH + LPS have differential effects on unique protein canonical signaling
pathways (Fig. 5.5A-B) related to transcription and translational signaling
pathways, as well as stress response pathways, for example: inactivation of Nrf2
(EtOH) and activation of the acute phase response or LXR/RXR (LPS) pathways.
Activation of hepatic LXRα is associated fatty liver pathogensis (172). Activation
of renal LXR has been shown to decrease cystic fibrosis transmembrane
conductance regulator (CFTR)-mediated chloride transport (173) and
downregulate sodium-phosphate cotransporters (173). The expected finding that
LPS activated the acute phase response pathway increased our confidence in
the unpredicted and novel findings, such as the overall inactivation of the Nrf2mediated oxidative stress response pathway (Fig. 5B).
EtOH-induced downregulation of select proteins in the Nrf2-mediated
oxidative stress response pathway was an unexpected finding, as EtOH is known
to induce Nrf2 through Cyp2E1 in the liver (174). Of the Nrf-2 targets, only Gclc
was down-regulated by NextGen transcriptomic data (mRNA log2FC -1.38, qvalue<0.007). In models of chronic kidney disease, Nrf2 pathway deactivation or
knock-out is known to cause injury from increased oxidative stress and/or death
(174-181). However, the EtOH-downregulation of proteins in the Nrf2 pathway
was not accompanied by significant renal injury as indicated by histology and
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magnitude of BUN increase. There are several possible explanations for this.
First, EtOH activation of other transcription factors (e.g. Ahr, Sp1, or AP-1)
successfully compensated for the downregulated components of the Nrf2
pathway and protected against injury (182-184). Second, the selective induction
of Nqo1 or Sod2 may be based on the binding to the antioxidant response
element (ARE) by unique Nrf2:cap n collar binding partner (e.g. Maf, MafF, MafB,
MafG, or PMF-1) complexes with targeted transcriptional activity (185-187).
Lastly, it is possible that neither the chronic, moderate EtOH consumption nor the
acute endotoxemia in these mice caused sufficient oxidative stress for the
decrease in select Nrf2 targets to be histologically deleterious.
EtOH-dependent reduction of Nrf2-related proteins may occur through one or
more of several potential mechanisms. Nrf2 is regulated by several mechanisms,
typically divided in to those dependent or independent of Kelch-like ECHassociated protein 1 (Keap1)(188). One mechanism involves Nrf2 activation
through the Sqstm1/p62-mediated deactivation of Keap1 (189). In the present
study, EtOH decreased Sqstm1/p62 abundance with or without LPS-exposure.
EtOH exposure of neuronal cells in culture has been shown to lead to an
activation of autophagic pathways that includes loss of Sqstm1/p62 (190).
Therefore, EtOH may deactivate the Nrf2 stress response pathway by induction
of autophagy, Sqstm1/p62 loss, and concomitant activation of Keap1. These and
other potential mechanisms of EtOH-induced dysregulation of the Nrf2-mediated
oxidative stress response pathway will be investigated in future studies.
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Cat (a Nrf2 target) abundance in the Lieber-DeCarli model decreased by 4050% while the CAT mRNA was stable (Log2FC -0.08, q<0.999). This suggests a
post-translational mechanism for decreased Cat abundance in the chronic
setting. We hypothesized this decrease would be more pronounced in a more
severe, acute-on-chronic NIAAA model (98) that better mimics human drinking
patterns. This would be an important finding as Cat plays a prominent role in
hydrogen peroxide degradation and of the three known EtOH oxidizing enzymes
(Ald, Cyp2E1, and Cat) is the most abundant in the renal cortex. Our data
demonstrated that in the NIAAA model, the chronic (10-day), acute (9h gavage),
and acute-on chronic EtOH consumption all decreased Cat abundance in the
renal cortex. The direct effects of EtOH on Cat will be investigated in future
studies.
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CHAPTER VI

DISCUSSION AND CONCLUSIONS

A. Restatement of goals and questions
The overall goal of the work described in this dissertation was to discover new
potential mechanisms of alcohol-induced organ injury. The work summarized in
Chapter III aimed to test a novel method of analyzing the hepatic matrisome and
use that approach to determine the effects of chronic, moderate ethanol
consumption and acute inflammation on the hepatic matrisome in mice. Chapter
IV aimed to characterize the ECM degradome (peptidome) in AH patient plasma
that will allow further investigation into the use of plasma ECM peptides as
surrogate or mechanistic biomarkers. Finally, Chapter V of this dissertation used
a discovery based ‘omics approach to elucidate the effects of ethanol
consumption on the kidneys. Taken together, these studies provide new
understanding of the complex mechanisms of alcohol-induced organ injury.

B. Major findings of this dissertation
1. The hepatic “matrisome” responds dynamically to stress
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The important role of the hepatic ECM in ALD pathophysiology is well known.
However, research on this topic has been largely ‘collagenocentric’ and
‘fibrosocentric’, that is, primarily focused on the role of the collagen matrix and
the dramatic ECM changes in the fibrosis stage of disease. It is now understood
that the ECM is not simply a collagen scaffold, but a complex microenvironment
that may be comprised of as many as 100 or more proteins at a time (191). The
group of proteins that makes up any specific ECM varies with organ and disease
state, and is a dynamic subset of over 1000 known ECM-related proteins (92). It
is therefore unsurprising that recent studies have shown that multiple ECM
proteins contribute to fibrosis (111). However, it is also now known that the
hepatic ECM is altered prior to fibrogenesis (89, 90). A limitation of previous
studies focused on the role of the ECM in ALD is that they generally studied
changes in one ECM protein at a time and did not consider structural changes
that may accompany altered ECM protein turnover. Therefore the goal of
Chapter III was to adapt a sequential protein extraction method originally
developed for cardiac tissue (99, 114, 121) to allow proteomic analysis of global
changes in the hepatic matrisome caused by chronic, moderate ethanol
consumption and acute inflammation (LPS). Furthermore, the sequential protein
extraction method reveals potential changes in ECM protein crosslinking,
location, and other aspects. Overall, this approach provides new insight into
novel matrisome protein changes caused by inflammatory stress.
This approach divided the hepatic ECM proteome into four distinct extracts:
(1) loosely-associated ECM proteins (NaCl extract), (2) intracellular and
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membrane-associated proteins (SDS extract), (3) tightly bound ECM proteins
(GnHCl extract), and (4) highly insoluble ECM components (the remaining pellet).
Qualitative analysis of the matrisome demonstrated that both ethanol and LPS
caused dynamic changes, with each exposure producing unique protein
abundance patterns across the four fractions. Indeed, ethanol and LPS each
increased the number of matrisome proteins by ~25% compared to control. The
combination of ethanol and LPS demonstrated patterns similar to each individual
exposure but also exhibited unique patterns. The unique subsets of proteins
qualitatively changed with ethanol and/or LPS may play critical roles in the
hepatic response to stress. Ethanol and/or LPS also quantitatively changed
abundance of many proteins that did not change qualitatively. These proteins
are new potential key players in liver injury, whose roles can be determined in
future studies. Furthermore, analysis of ethanol-specific matrisome changes
may provide new insights into the mechanisms of ethanol-sensitized liver injury,
which could reveal novel therapeutic targets. Most importantly, this work
demonstrates the dynamic, global response of the hepatic matrisome to stress
that opens a new, important area of future research. This work also lays the
foundation for future studies, such as the investigation of the ECM degradome in
the plasma of AH patients described in Chapter IV.

2. The plasma ECM degradome profile of alcoholic hepatitis patients
changes between MELD groups
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Chapter IV of this dissertation aimed to characterize the plasma peptidome in
AH patients. This builds upon the work described in Chapter III of this
dissertation, which demonstrated that the hepatic ECM undergoes significant
remodeling during inflammatory liver injury in the absence of any apparent
fibrosis (93). This remodeling involves protease cleavage of ECM proteins,
which yields ECM peptide fragments (94). During remodeling, peptide fragments
of the degraded ECM have been shown to increase in biologic fluids (e.g.
plasma) (58, 59). Peptidomic analysis of the degraded ECM (i.e., ‘degradome)
has been identified as a useful diagnostic/prognostic tool in other diseases of
ECM remodeling (such as metastatic cancers)(58, 59). Current methods of
predicting AH outcome (i.e. clinical scores, e.g. MELD) are limited in their abilities
to predict at-risk patients with moderate disease(84). We hypothesized that the
severe inflammatory liver injury caused by AH would yield a unique degradome
profile in patient plasma.
In the pilot study described herein, a workflow was developed for the
peptidomic analysis of plasma from healthy participants or AH patients. AH
severity was stratified by MELD score as mild (<12; n=45), moderate (12-19;
n=23) or severe (>19; n=37). Hierarchical clustering of the peptidomic data
identified three strong groupings of peptide abundance patterns that reflected
combinations of (A) increased peptide levels in healthy controls, (B) increased
peptide levels in Moderate + Severe and (C) increased peptide levels in Mild-A +
Mild-B AH cohorts. Post-hoc filtering of the differentially abundant peptides
identified strong relative abundance changes in ECM peptides with strong
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differences noted in the collagen and fibrinogen peptides. The unique patterns of
ECM and other plasma peptides ‘features’ across different severity groups of AH
patients can be confirmed using large longitudinal studies and can be
investigated further as potential mechanistic or surrogate biomarkers for patient
outcome. The characterization of the AH plasma degradome also supports
future mechanistic studies on the role of ECM remodeling in AH.

3. Alcohol consumption alters renal cortical oxidant response
pathways
The studies in Chapter III and Chapter IV focus on the toxic effects of ethanol
on its primary target organ, the liver. In contrast to the liver, the effects of ethanol
consumption on the kidneys are poorly understood. Some human studies have
reported benefits of chronic moderate EtOH consumption for preservation of
renal function (85, 95). However, the small number of rodent studies on the
effects of ethanol on the kidneys have reported that chronic ethanol consumption
upregulates CYP2E1 (88), causes neutrophil infiltration (88), and increases
acetylation of mitochondrial proteins (86) in the kidney. However, these previous
studies have been limited by the hypothesis that ethanol affects the kidneys by
mechanisms parallel to those in the liver. To bypass this limitation, the study in
Chapter V used an unbiased proteomic and transcriptomic approach to discover
novel players and pathways affected by ethanol and LPS in the renal cortex.
The proteomic analysis found that EtOH significantly changed 92, 14, and
109 proteins on a control, 4h LPS, and 24h LPS background, respectively.
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Interestingly, ethanol significantly decreased the abundance of a cluster of
peroxisomal proteins compared to control. Ethanol also increased the
abundance of a cluster of ribosomal proteins on a background of 24-hour LPS.
The effects of ethanol on the transcriptome were more muted than the effects on
the proteome, suggesting that ethanol-induced protein may occur through
degradation or other transcription-independent mechanisms. Pathways analysis
of integrated proteomic and transcriptomic data revealed that ethanol caused
overall inactivation of the Nrf2-mediated oxidative stress response pathway. This
finding, which was confirmed with western blots, was surprising, as ethanol is
known to induce Nrf2 in the liver (174). This demonstrates the benefit of an
unbiased, discovery-based approach. Chronic ethanol consumption decreased
Cat (a Nrf2 target) abundance by 40-50%. The EtOH-associated effects on Cat
were confirmed using a separate chronic-plus-binge (NIAAA) model. This work
uncovers novel potential mechanisms by which ethanol effects the kidneys that
can be studied further in the future. Most importantly, these findings reveal that
chronic, moderate ethanol consumption affects the renal cortex at the protein and
transcript level in the absence of tissue-level changes.

C. Significance of new findings
Chapter III describes a new method of analyzing the hepatic matrisome and
revealed that the hepatic matrisome responds dynamically to stress. The
significance of this new method is that it can be adapted for analysis of the
matrisome in other liver pathologies (e.g., NAFLD) and in other organs (e.g., the
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lung). The finding that the hepatic matrisome responds dynamically to
inflammatory stress is significant in that it provides a mechanistic link between
steatohepatitis and fibrogenesis. That ‘link’ is transitional ECM remodeling,
which is thought to be a pivotal point between disease restitution and progression
(1), and is therefore a promising target for new therapeutics. The work in
Chapter III identified specific protein players involved in remodeling that can be
investigated as drug targets in future studies. Furthermore, as ECM remodeling
yields degradation products that can be secreted into bodily fluids, knowledge of
remodeling also supports future investigations of the degradome (e.g. Chapter
IV) and the eventual development of novel biomarkers.
Plasma peptidomics is a novel approach for prognosis stratification in AH.
The work in Chapter IV found that peptides in the plasma of AH patients change
across groups separated by MELD score. Interestingly, patients with lower
MELD scores had dramatically higher abundances of plasma peptides than those
with higher MELD scores. This suggests that the degradome may be a positive
predictor of outcome in AH. Patient prognosis is a key factor in clinical riskbenefit decision making regarding the administration of anti-inflammatory
pharmacotherapeutics. While this work could lead to novel surrogate
biomarkers, understanding the peptidome can also provide insight into AH
mechanisms. For example, the peptidome in Chapter IV can be used to predict
the proteases that generated it. This protease activity can be validated and
targeted in future studies, which could lead to new targeted therapies for AH.
Furthermore, the plasma peptides resulting from the protease activity could serve
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as mechanistic biomarkers for response to the targeted therapy. Even apart from
these possibilities, the fact that this work demonstrated that acute hepatic
inflammation yields widespread, measurable changes in the plasma peptidome is
significant in itself.
The effects of ethanol consumption on the kidneys are poorly understood.
The work in Chapter V demonstrated that although ethanol consumption does
not cause histologically detectable changes in renal architecture, it does
influence the renal cortex proteome and, to a lesser extent, transcriptome. For
example, ethanol consumption caused overall inactivation of the Nrf2 pathway,
decreased abundance of peroxisomal proteins, and attenuated induction of LPSresponsive genes. This suggests unique effects of ethanol on the kidney that do
not parallel those in the liver. These data provide new hypotheses for future
investigations on both the direct effects of ethanol on the kidneys and effects of
ethanol on other renal pathologies. More broadly, insight into the effects of
ethanol on the kidneys contributes to understanding of alcohol toxicity, which
could lead to new hypotheses and therapeutic approaches in the study of ALD.

D. Strengths and weaknesses of this dissertation
1. Strengths
There are several strengths of this dissertation. The first study provides
insight into the role of transitional ECM changes in ethanol-sensitized hepatic
inflammation (Chapter III) by characterizing the hepatic matrisome. This work
used a well-established mouse model of chronic, moderate ethanol consumption
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and subsequent LPS exposure. Ethanol-sensitized hepatic inflammation is a
complex phenomenon that is not confined to a single organ or cell type and
cannot be wholly recapitulated in a simpler model (e.g. cell culture). The use of
an animal model as opposed to a human study allows many variables to be
controlled, such as number of calories consumed, genetic variability, and
environmental factors. This increases confidence that ethanol and/or LPS are
the variables that caused the experiment results. Another strength is that a new
method of protein extraction was validated for use with liver tissue, enabling the
analysis of low-abundance and highly insoluble hepatic ECM proteins. This
allowed for a discovery-based proteomic characterization of the matrisome that
provides a foundation for new hypothesis-driven studies and the identification of
new therapeutic targets. Importantly, this work also demonstrates that the
hepatic matrisome responds dynamically to stress in the absence of fibrosis.
The second study in this dissertation examines the plasma peptidome from
AH patients with disease severity stratified by MELD score. This investigation
uses plasma from human patients, and so it does not rely on assumptions
regarding the relevance of a model. Another strength is that several different
methods for the purification of peptides were tested, and the method which
yielded the most pure peptidome was chosen. Samples were handled randomly
in flights that contained a number of samples from each group that was
proportional to the total. This minimizes any bias caused by sample handling.
Samples were also spiked with a peptide standard prior to LC-MS/MS analysis to
control for time-dependent changes in the instrument. Additionally, the statistical
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analysis of the peptidomic data accounted for several covariates, including
participant age and sex. The analysis included in this dissertation is preliminary,
and future analyses will ensure that all appropriate covariates are considered.
Another strength of this study is that patient plasma, as opposed to liver tissue,
was analyzed. This supports the future development of a minimally invasive
diagnostic tool.
The third study in this dissertation examines the effects of ethanol
consumption on the renal cortex proteome and transcriptome. This work
employed the same mouse model of chronic, moderate ethanol consumption and
a second ‘hit’ of LPS used in the first study in this dissertation. Therefore, the
same strengths associated with this model apply. This model is well established
and recapitulates the complexity of human alcohol consumption, while still
controlling many variables. Another strength of this work is that the proteomic
workflow included TMT labeling, which allows reliable relative quantification of
proteins between experimental groups. This work also used a discovery-based
‘omics approach, as opposed to a hypothesis driven approach. Hypotheses by
nature rely on previous knowledge, but very little is currently known about the
effects of ethanol on the kidneys. For this reason, a hypothesis-generating
approach was chosen, which provides a foundation for future studies. Indeed,
several effects of ethanol on the kidneys were identified which would not have
previously been expected. It should also be noted that expected LPS-activation
of the acute phase response pathway was observed, which can be viewed as a
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“positive control” that increases confidence in the less expected results of this
study.

2. Weaknesses
The experiments described in Chapter III identified changes in the hepatic
matrisome after alcohol and LPS exposure. Although there are strengths
associated with the use of a mouse model, there are also limitations that should
be acknowledged. Although in vivo experiments may recapitulate human
disease more completely compared to in vitro experiments, in vivo research
introduces more complexity and less control of variables. Conversely, relevance
to human disease may be questionable when mouse models are compared to
human studies. It is therefore possible that the observed matrisome changes are
mouse-specific and have little direct relevance to humans. While the inverse
relationship between model relevance and ability to control variables can never
be entirely avoided, it can be optimized for the question at hand and thoughtfully
considered when interpreting results. Another limitation of this study is that the
biological replicate samples from the same fraction and same experimental group
were pooled prior to LC-MS/MS analysis due to cost and time constraints. This
means that a sample from a single mouse could have driven the observed
qualitative changes in protein abundance. For this reason, follow-up studies are
needed to confirm specific matrisome protein changes caused by ethanol and/or
LPS. Additionally, this study did not investigate the functional significance of
specific protein changes, and so future studies should address this.
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The work in Chapter IV identified plasma peptides that change with disease
severity in AH patients. As with all human studies, there are many variables that
cannot be controlled, and should therefore be included as covariates in statistical
analyses. The analyses included herein consider age and sex as covariates, but
do not include other covariates, such as body mass index or race. Plasma from
different study groups was also collected at different sites, and so site-specific
changes need to be statistically accounted for to the extent possible. Therefore,
it is possible that variables other than AH severity may be involved in the
observed changes in peptide abundances. As noted previously, the statistical
analysis in this dissertation is a pilot study, and future analyses will more
thoroughly address potential confounding variables. Another limitation of this
study is that it is cross-sectional, and so large scale longitudinal follow-up studies
are needed to confirm the use of select peptides for outcome prediction.
The work in Chapter V identifies proteins, transcripts and pathways affected
by ethanol and/or LPS in the renal cortex. The same mouse model was used in
Chapter III. Therefore, the same model-related limitations apply that were
previously discussed. As with any animal model, the relevance of the
experimental results to human disease is not guaranteed, and neither is the
assumption that all potential confounding variables have been controlled. It
should also be acknowledged that another study reported that a similar rat model
of chronic ethanol consumption increased recruitment of MPO-positive cells into
the kidney, whereas we did not observe this effect (87). Another limitation is that
TMT labeling, which is used for relative quantification of protein abundance, is
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known to cause signal suppression. Therefore, the observed protein-level
changes caused by ethanol and/or LPS may actually be greater than what was
observed. Additionally, it is standard practice to confirm phenomena of interest
observed with an ‘omics approach using an additional method (e.g. immunoblot
to confirm proteomics). Some protein-level changes reported here were indeed
confirmed with immunoblot, but other changes need to be confirmed in future
studies.

E. Future Directions
While the experiments described in this dissertation answered specific gaps
in our knowledge of alcohol-induced organ injury, it has also created new
questions that will need to be addressed in future studies. Three of these
questions of these are discussed below.

1. Does targeting the regulated “matrisome” proteins identified in
Chapter III prevent, halt, or reverse alcohol-induced organ injury?
The method described in Chapter III identified dynamic changes in the
hepatic matrisome after ethanol and/or LPS exposure. However, whether any of
these ECM proteins plays a critical role in alcohol-sensitized liver injury has yet to
be determined. To carry out this investigation, a select matrisome protein that
was strongly and uniquely affected by ethanol in Chapter III could be genetically
or pharmacologically targeted in a mouse model. These mice could be
administered the same model of chronic ethanol exposure followed by
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inflammatory insult used in Chapter III. Hepatic inflammatory injury in these mice
could be examined with histology or other methods. If targeting a protein
mitigates damage, then that protein plays a critical role in damage. For example,
previous studies from our group demonstrated that the integrin inhibitor
CycloRGDfV protects against liver injury and inflammation caused by acute
ethanol exposure and LPS (192). Such findings would support the targeting of
the matrisome protein as a therapeutic strategy.

2. Do the regulated peptides and features identified in Chapter IV
predict alcoholic hepatitis patient outcome and/or response to
treatment in longitudinal studies?
The study in Chapter IV identifies plasma peptides of AH patients that change
in abundance with disease severity. Earlier in the discussion, it was noted that a
limitation of this study is that it is cross-sectional and therefore does not follow
the same patients over time. Since this research asks the question whether
peptide “features” can predict AH outcome, follow-up longitudinal outcome
studies would help answer this question more definitively. Such studies could
also investigate the ability of regulated peptide “features” to predict response to
treatment

3. What are the mechanisms by which alcohol consumption alters the
oxidant response pathways identified in Chapter V in the renal
cortex?
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The experiments described in Chapter V identified the effects of ethanol
consumption on renal cortex proteins and pathways using a discovery-based
‘omics approach. The mechanisms by which ethanol elicits these effects are
unknown. The transcriptomic analysis in Chapter V revealed that the effects of
ethanol on the transcriptome were more muted than the effects on the proteome,
suggesting that ethanol-induced protein changes may occur through altered
protein degradation or other transcription-independent mechanisms. Targeting
one of these mechanisms in the same model of ethanol consumption used in
Chapter V would help determine the contribution of that mechanism to the
observed ethanol-induced effects. Since the ethanol-induced effects have
already been identified, they can now be detected with a more targeted method
(e.g. immunoblot or PCR) instead of an ‘omics approach. Additionally, molecular
signaling programs (e.g. phosphorylation cascades) likely play a role in
regulating the observed changes in protein abundance, and could be
investigated with a proteomic approach (e.g. phosphoproteomics), or other
methods. It should be noted that others have used acetylomics to determine that
chronic, moderate ethanol consumption causes mitochondrial hyperacetylation in
rodent kidneys (86). Links between this acetylomic data and the results in
Chapter V could be investigated in future studies.

F. Summary and Conclusions
The overall goal of the work described in this dissertation was to elucidate
mechanisms of alcohol-induced organ injury. Chapter III introduced a new
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proteomic approach for characterizing the hepatic matrisome. That approach
was used to characterize the dynamic response of the matrisome to the stress of
chronic, moderate ethanol consumption and acute inflammation in mice. This
provides a foundation for future experiments to identify new players in transitional
ECM remodeling. Chapter IV demonstrated that AH causes detectable changes
in the plasma ECM degradome/peptidome of patients. These findings will allow
future investigations into the use of plasma peptide ‘features’ as biomarkers for
AH outcome. Finally, Chapter V revealed the effects of chronic ethanol
consumption and acute inflammation on the renal cortex proteome and
transcriptome. This work provides new hypotheses for future studies examining
the effects of ethanol on the kidneys. Taken together, this work reveals new
insight into mechanisms by which ethanol affects the liver and kidneys.
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ABBREVIATIONS
Adh

Alcohol dehydrogenase

AH

Alcoholic hepatitis

Ahr

Aryl hydrocarbon receptor

ALD

Alcoholic liver disease

ANOVA

Analysis of variance

Aldh

Aldehyde dehydrogenase

ALT

Alanine aminotransferase

APP

Acute phase protein

ARE

Antioxidant response element

ASH

Alcoholic steatohepatitis

AST

Aspartate aminotransferase

AUC

Area under the curve

AUD

Alcohol use disorder

AUDIT

Alcohol use disorder identification test

BH

Benjamini-Hochberg

BSA

Bovine serum albumin

BUN

Blood urea nitrogen

Cat

Catalase

CCL2

C-C Motif Chemokine Ligand 2

CID

Collision induced dissociation

COL

Collagen

CRELD2

Cysteine-rich with EGF-like domain protein 2

CTP

Child-Turcotte-Pugh score

Cyp2e1

Cytochrome P450 2E1

DAMP

Damage-associated molecular pattern
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DSM

Diagnostic and Statistical Manual of Mental Disorders

DTT

Dithiothreitol

ECM

Extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

ER

Endoplasmic reticulum

ETD

Electron transfer dissociation

EtOH

Ethanol

FA

Formic acid

FASP

Filter-aided sample preparation

FC

Fold change

FDR

False discovery rate

FTMS

Fourier-transform mass spectrometry

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

Gclc

Glutamate-cysteine ligase catalytic subunit

GnHCl

Guanidine hydrochloride

GO

Gene ontology

H&E

Hematoxylin & eosin

HC

Healthy control

HCC

Hepatocellular carcinoma

HCD

Higher energy collision dissociation

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HF

Hepatic fibrosis

HLB

Hydrophilic-lipophilic balance

HMGB1

High mobility group protein B1

HRS

Hepatorenal syndrome

HSCs

Hepatic stellate cells

IFN-γ

Interferon gamma

IB

Immunoblot

i.p.

Intraperitoneal
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IHC

Immunohistochemistry

INR

International normalized ratio

IPA

Ingenuity Pathways Analysis

ITMS

Ion trap mobility spectrometry

KCl

Potassium chloride

KCs

Kupffer cells

Keap1

Kelch-like ECH-associated protein 1

LC-MS/MS

Liquid chromatography and tandem mass spectrometry

LPS

Lipopolysaccharide

LTDH

Lifetime drinking history

LXR

Liver X receptor

M/z

Mass-to-charge ratio

MD

Maltose-dextrin

MDE

Matrix-degrading enzymes

MELD

Model for end-stage liver disease

MMPs

Matrix metalloproteinases

Mpo

Myeloperoxidase

mRNA

Messenger ribonucleic acid

MS

Mass spectrometry

NaCl

Sodium chloride

NaF

Sodium fluoride

NAFLD

Non-alcoholic fatty liver disease

NASH

Non-alcoholic steatohepatitis

NaVO3

Sodium metavanadate

NIAAA

National Institute on Alcohol Abuse and Alcoholism

NIH

National Institutes of Health

NP-40

Nonidet p-40

Nqo1

NAD(P)H quinone dehydrogenase 1

Nrf2

Nuclear factor erythroid 2–related factor 2
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PAI-1

Plasminogen activator inhibitor

PAMP

Pathogen-associated molecular pattern

PAS

Periodic acid-Schiff

PBDC

Proteomics Biomarkers Discovery Core

PCA

Principle component analysis

PEBP1

Phosphatidylethanolamine-binding protein

PMN

Polymorphonuclear leukocyte

PRR

Pathogen recognition receptor

PT
RANTES

Prothrombin time
Regulated on activation, normal T cell expressed and
secreted

RIN

RNA integrity number

RIPA

Radioimmunoprecipitation assay

RNA

Ribonucleic acid

RXR

Retinoid X receptor

SAA1

Serum amyloid A1

SAA2

Serum amyloid A2

SCX

Strong cation exchange

SDS

Sodium dodecyl sulfate

SGOT

Serum glutamic oxaloacetic transaminase

SGPT

Serum glutamic-pyruvic transaminase

SIRS

Systemic inflammatory response syndrome

Sod1

Superoxide dismutase 1

Sod2

Superoxide dismutase 2

Sqstm

Sequestrome-1

Tbili

Total bilirubin

TBST

Tris-buffered saline and Tween

TCA

Trichloroacetic acid

TEABC

Triethylammonium bicarbonate

TGFβ

Transforming growth factor beta
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TIC

Total ion current

TIMP

Tissue inhibitor of matrix metalloproteinases

TLR4

Toll-like receptor 4

TNFα

Tumor necrosis factor-alpha

TMT

Tandem mass tag

UHPLC

Ultra-high-performance liquid chromatography
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2018-present

Kentucky Academy of Science (KAS)

2016-2018

Kentucky Biomedical Research Infrastructure and Network
(KBRIN) Journal Club

2016-2017

American Society of Nephrology (ASN)
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2015-present

American Association for the Study of Liver Diseases (AASLD)

2014-present

University of Louisville Alcohol Research Center (ULARC)

2014-present

Society of Toxicology (SOT), Student Member

2014-present

Ohio Valley Society of Toxicology (OVSOT)

4. AWARDS AND HONORS
2018

Abstract awarded “Best of the Liver Meeting”, AASLD’s Liver Meeting

2018

Invited to speak at Early Morning Workshop, AASLD’s Liver Meeting

2018

Abstract selected for oral presentation, AASLD’s Liver Meeting

2017

Abstract selected for oral presentation, OVSOT Fall Meeting

2017

Finalist in University of Louisville Three-Minute Thesis Competition

2016

Graduate Student Council Travel Award

2016

Abstract selected for oral presentation, OVSOT Summer Meeting

2015

Poster selected for third and final round of judging, Research!Louisville

2015

Abstract selected for oral presentation, OVSOT Summer Meeting

2015

One of seven University of Louisville undergraduate students selected
to present research at the Atlantic Coast Conference Meeting of the
Minds

2010

Valedictorian and Summa cum Laude, South Oldham High School

2009

Kentucky Governor’s Scholars Program, focus in Biological and
Environmental Issues

5. SERVICE AND LEADERSHIP ACTIVITIES
02/2019

Organized and led presentation and activity for Westport Middle
School Girls’ STEM Club, through the Kentucky Academy of Science

08/2018

Served on Q&A panel for new student welcome event, Department of
Pharmacology and Toxicology, University of Louisville

07/2018

Collected clinical data for Superfund “Project Greenheart”, University
of Louisville

07/2018

Led roundtable discussion for National Cancer Institute R25 Cancer
Education Program students, University of Louisville

07/2016

Led roundtable discussion for National Cancer Institute R25 Cancer
Education Program students, University of Louisville

08/2012-05/2013

Served on the University of Louisville Housing and Residence Life
“Green Committee”, which promotes sustainability in residence halls
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6. FUNDING
2017-present

National Institute of Environmental Health Sciences NRSA
Institutional Training Grant (T32) Predoctoral Fellowship,
University of Louisville, Department of Pharmacology and
Toxicology

2015-2017

Graduate Research Fellowship, Integrated Program in Biomedical
Sciences, University of Louisville

7. ABSTRACTS AND PRESENTATIONS
A. Abstracts
Local/Regional
1. Dolin CE, Wilkey DW, Vatsalya V, McClain CJ, Merchant ML, Arteel GE.
Poster, (2018) Peptidomic analysis of alcoholic hepatitis: a new prognostic
tool? Research!Louisville, Louisville, KY.
2. Dolin CE, Poole LG, Wilkey DW, Arteel GE, Rouchka EC, Barati MT,
Merchant ML. (2017) A novel effect of alcohol on the kidney: Chronic and
acute alcohol exposure alter peroxisomal protein abundance in the renal
cortex. Ohio Valley Society of Toxicology Annual Meeting, West Lafayette,
IN.
3. Hudson SV, Dolin CE, Merchant ML, Arteel GE (2017) Arsenic Attenuates
LPS-stimulated Polarization in Murine Bone Marrow Derived Macrophages:
Potential Role of miR-301b. Research!Louisville, Louisville, KY.
4. Dolin CE, Poole LG, Wilkey DW, Arteel GE, Rouchka EC, Barati MT,
Merchant ML. (2017) A novel effect of alcohol on the kidney: Chronic and
acute alcohol exposure alter peroxisomal protein abundance in the renal
cortex. Research!Louisville, Louisville, KY.
5. Dolin CE, Poole LG, Wilkey DW, Rouchka EC, Arteel GE, Barati MT,
Michael L. Merchant. (2017) Effects of ethanol and lipopolysaccharide on
the renal cortex proteome and transcriptome. UT-KBRIN Bioinformatics
Summit, Burns, TN.
6. Dolin CE, Poole LG, Wilkey DW, Rouchka EC, Arteel GE, Barati MT,
Michael L. Merchant. (2017) Effects of ethanol and lipopolysaccharide on
the renal cortex proteome and transcriptome. Graduate Student Council
Research Symposium, Louisville, KY.
7. Dolin CE, Poole LG, Wilkey DW, Arteel GE, Rouchka EC, Barati MT,
Merchant ML. (2016) Effects of Ethanol and Lipopolysaccharide on the
Renal Cortex Proteome and Transcriptome. Ohio Valley Society of
Toxicology Annual Meeting, Indianapolis, IN.
8. Poole LG, Beier JI, Torres-Gonzalez E, Anwar-Mohamed A, Warner N,
Dolin CE, Nguyen-Ho C, Hudson SV, Roman J, Arteel GE. (2016) Acuteon-chronic Alcohol Exposure Concomitantly Damages the Liver and Lung.
Research!Louisville, Louisville, KY.
9. Hudson SV, Dolin CE, Poole LP, Massey VL, Wilkey DW, Merchant ML,
Frieboes H, Arteel GE. (2016) Modeling Binding Kinetics of Integrin
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Mediators of EtOH-enhanced LPS Liver Injury. Research!Louisville,
Louisville, KY.
10. Dolin CE, Poole LG, Wilkey DW, Arteel GE, Rouchka EC, Barati MT,
Merchant ML. (2016) Effects of Ethanol and Lipopolysaccharide on the
Renal Cortex Proteome and Transcriptome. Research!Louisville, Louisville,
KY.
11. Dolin CE, Poole LG, Wilkey DW, Barati MT, Arteel GE, Merchant ML. (2016)
Characterization of the Impact of Ethanol and Lipopolysaccharide on the
Renal Cortex Proteome. Ohio Valley Society of Toxicology Summer
Meeting, Cincinnati, OH.
12. Dolin CE, Poole LG, Wilkey DW, Barati MT, Arteel GE, Merchant ML. (2016)
Characterization of the Impact of Ethanol and Lipopolysaccharide on the
Renal Cortex Proteome. University of Kentucky Postdoctoral Symposium,
Lexington, KY.
13. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW,
Roman J, Arteel GE. (2016) The Hepatic and Pulmonary “Matrisomes”
Respond Dynamically to Inflammatory Injury: Proteomic Characterization of
Transitional ECM Changes in the Liver and Lung. Graduate Student Council
Research Symposium, Louisville, KY.
14. Poole LG, Massey VL, Torres-Gonzalez E, Warner N, Siow D, Dolin CE,
Lang AL, Hudson SV, Roman J, Arteel GE. (2015) Alcohol enhances
endotoxemia-induced acute lung injury: role of plasminogen activator
inhibitor-1. Research!Louisville, Louisville, KY.
15. Hudson SV, Dolin CE, Poole LP, Massey VL, Wilkey DW, Merchant ML,
Frieboes H, Arteel GE. (2015) Modeling the Kinetics of Integrin Receptor
Binding to Extracellular Matrix Proteins. Research!Louisville, Louisville, KY.
16. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW,
Roman J, Arteel GE. (2015) The Hepatic and Pulmonary “Matrisome”
Responds Dynamically to Inflammatory Injury: Proteomic Characterization
of the Transitional ECM Changes. Research!Louisville, Louisville, KY.
17. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2015) The Hepatic “Matrisome” Responds Dynamically to
Inflammatory Injury: Proteomic Characterization of the Transitional ECM
Changes in the Liver. Ohio Valley Society of Toxicology Summer Meeting,
Cincinnati, OH.
18. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2015) The Hepatic “Matrisome” Responds Dynamically to Stress:
Novel Characterization of the ECM Proteome. Atlantic Coast Conference
Meeting of the Minds, Raleigh, NC.
19. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2015) The Hepatic “Matrisome” Responds Dynamically to Stress:
Novel Characterization of the ECM Proteome. Posters at the Capitol,
Frankfort, KY.
20. Poole LG, Massey VL, Dolin CE, Siow DL, Merchant ML, Beier JI, Roman
J, Arteel GE. (2014) Ethanol-induced changes in the hepatic ECM directly
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enhance the pro-inflammatory response of macrophages. Ohio Valley
Society of Toxicology Annual Meeting, Dayton, OH.
21. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2014) The Hepatic “Matrisome” Responds Dynamically to Stress:
Novel Characterization of the ECM Proteome. Ohio Valley Society of
Toxicology Annual Meeting, Dayton, OH.
22. Massey VL, Poole LG, Torres E, Dolin CE, Merchant ML, Ritzenthaler J,
Roman J, Arteel GE. (2014) Characterization of the liver:lung axis in alcoholinduced lung damage. Research!Louisville, Louisville, KY.
23. Poole LG, Massey VL, Dolin CE, Merchant ML, Beier JI, Roman J, Arteel
GE. (2014) Ethanol-induced changes in the hepatic ECM directly enhance
the pro-inflammatory response of macrophages. Research!Louisville,
Louisville, KY.
24. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE (2014) The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. Research!Louisville, Louisville, KY.
25. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE (2014) The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. University of Louisville R25 Cancer
Education Program, Louisville, KY.
National
1.

Dolin CE, Wilkey DW, Vatsalya V, Srivastava S, McClain CJ, Rai SN,
Merchant ML, Arteel GA (2018) Novel Biomarkers in Alcoholic Hepatitis:
Analysis of the Plasma Peptidome/Degradome. Hepatology 68(6):1444A.

2.

Hudson SV, Anwar-Mohamed A, Dolin CE, Merchant ML, Arteel GE (2017)
Arsenic Attenuates Lipopolysaccharide-Stimulated Polarization in Murine
Bone Marrow Derived Macrophages: Potential Role of miR-301b. The
Toxicologist Supplement 2017:2992.

3.

Hudson SV, Dolin CE, Merchant ML, Arteel GE (2017) Role of miR-301b in
arsenic-altered macrophage polarization: potential insight into impact of
arsenic exposure on innate immune response. Hepatology 66(S1):653.

4.

Poole LG, Beier JI, Torres-Gonzalez E, Anwar-Mohamed A, Warner N,
Dolin CE, Nguyen-Ho C, Ritzenthaler JD, Roman J, Arteel GE (2016)
Acute-on-chronic alcohol exposure using the ‘NIAAA model’ concomitantly
damages the liver and lung. Hepatology 64(S1):1221.

5. Hudson SV, Dolin CE, Poole LG, Massey VL, Wilkey DW, Brock GN,
Merchant ML, Frieboes HB, Arteel GE (2016) Modeling Concurrent Binding
of Mixed Integrin Species to Multiple ECM Ligands. The Toxicologist
Supplement 2016:2211.
6. Dolin CE, Poole LG, Wilkey DW, Arteel GE, Rouchka EC, Barati MT,
Merchant ML (2016) Omics Characterization of Ethanol and
Lipopolysaccharide Impact on the Renal Cortex. JASN Abstract Supplement
2016 27:
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7. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2015) The Hepatic and Pulmonary “Matrisome” Responds Dynamically
to Inflammatory Injury: Proteomic Characterization of the Transitional ECM
Changes in the Liver. Hepatology 62(S1):587.
8. Dolin CE, Massey VL, Poole LG, Siow DL, Merchant ML, Wilkey DW, Arteel
GE. (2015) The Hepatic “Matrisome” Responds Dynamically to Stress:
Novel Characterization of the ECM Proteome. The Toxicologist Supplement
2015:693.
B. Oral Presentations
Local/Regional
1. 12/2018. Research Seminar. Using proteomics to discover new
mechanisms and biomarkers in alcohol-induced organ injury. Department of
Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY.
2. 3/2018. Journal Club Presentation. Time and compartment resolved
proteome profiling of the extracellular niche in lung injury and repair- Schiller
et al. Kentucky Biomedical Research Infrastructure Network (KBRIN)
Journal Club, Louisville, KY.
3. 12/2017. Platform Presentation, 12/2017, A novel effect of alcohol on the
kidney: Chronic and acute alcohol exposure alter peroxisomal protein
abundance in the renal cortex. Ohio Valley Society of Toxicology Annual
Meeting, West Lafayette, IN.
4. 4/2017. Research Seminar. A systems-based approach to discover alcoholinduced mechanisms in the liver, lung, and kidney. Department of
Pharmacology and Toxicology, University of Louisville, Louisville, KY.
5. 3/2017. Platform Presentation. Effects of ethanol and lipopolysaccharide on
the renal cortex proteome and transcriptome. Graduate Student Council
Research Symposium, Louisville, KY.
6. 3/2017. Research Seminar. A systems-based approach to discover alcoholinduced mechanisms in the liver, lung, and kidney. KBRIN Bioinformatics
Group, University of Louisville, Louisville, KY.
7. 6/2016. Platform Presentation. Characterization of the Impact of Ethanol
and Lipopolysaccharide on the Renal Cortex Proteome. Ohio Valley Society
of Toxicology Summer Meeting, Cincinnati, OH.
8. 6/2016. Research Seminar. Proteomic Characterization of the Impact of
Alcohol-Enhanced Inflammatory Injury on the Liver, Lung, and Kidney.
Department of Pharmacology and Toxicology, University of Louisville,
Louisville, KY.
9. 6/2015. Platform Presentation. The Hepatic “Matrisome” Responds
Dynamically to Inflammatory Injury: Proteomic Characterization of the
Transitional ECM Changes in the Liver. Ohio Valley Society of Toxicology
Summer Meeting, Cincinnati, OH.
National
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1. 11/2018. Platform Presentation. Novel biomarkers in alcoholic hepatitis:
analysis of the plasma peptidome/degradome. American Association for the
Study of Liver Diseases’ The Liver Meeting, San Francisco, CA.
2. 11/2018. Early Morning Workshop Presentation. The hepatic “matrisome”
responds dynamically to injury: characterization of transitional changes to
the extracellular matrix in mice. American Association for the Study of Liver
Diseases’ The Liver Meeting, San Francisco, CA.
C. Posters
Local/Regional
1. 10/2018. Peptidomic analysis of alcoholic hepatitis: a new prognostic tool?
Research!Louisville, Louisville, KY.
2. 9/2017. A novel effect of alcohol on the kidney: Chronic and acute alcohol
exposure alter peroxisomal protein abundance in the renal cortex,
Research!Louisville, Louisville, KY.
3. 4/2017. Effects of ethanol and lipopolysaccharide on the renal cortex
proteome and transcriptome, UT-KBRIN Bioinformatics Summit, Burns, TN.
4. 10/2016. Effects of Ethanol and Lipopolysaccharide on the Renal Cortex
Proteome and Transcriptome. Ohio Valley Society of Toxicology Annual
Meeting, Indianapolis, IN.
5. 10/2016. Effects of Ethanol and Lipopolysaccharide on the Renal Cortex
Proteome and Transcriptome. Research!Louisville, Louisville, KY.
6. 6/2016. Characterization of the Impact of Ethanol and Lipopolysaccharide
on the Renal Cortex Proteome. University of Kentucky Postdoctoral
Symposium, Lexington, KY.
7. 4/2016. The Hepatic and Pulmonary “Matrisomes” Respond Dynamically to
Inflammatory Injury: Proteomic Characterization of Transitional ECM
Changes in the Liver and Lung. Graduate Student Council Research
Symposium, Louisville, KY.
8. 10/2015. The Hepatic and Pulmonary “Matrisome” Responds Dynamically
to Inflammatory Injury: Proteomic Characterization of the Transitional ECM
Changes. Research!Louisville, Louisville, KY.
9. 2015. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. Atlantic Coast Conference Meeting
of the Minds, Raleigh, NC.
10. 2014. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. Ohio Valley Society of Toxicology
Annual Meeting, Dayton, OH.
11. 9/2014. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. Research!Louisville, Louisville, KY.
12. 2014. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. University of Louisville National
Cancer Institute R25 Cancer Education Program, Louisville, KY.
204

National
1. 11/2016. Omics Characterization of Ethanol and Lipopolysaccharide Impact
on the Renal Cortex. American Society of Nephrology Kidney Week,
Chicago, IL.
2. 11/2015. The Hepatic and Pulmonary “Matrisome” Responds Dynamically to
Inflammatory Injury: Proteomic Characterization of the Transitional ECM
Changes in the Liver. American Association for the Study of Liver Diseases’
The Liver Meeting, San Francisco, CA.
3. 3/2015. The Hepatic “Matrisome” Responds Dynamically to Stress: Novel
Characterization of the ECM Proteome. Society of Toxicology Annual
Meeting, San Diego, CA.
8. PUBLICATIONS
A. Papers
As coauthor
1. Hudson SV, Dolin CE, Merchant ML, and Arteel GE. Arsenic attenuates
lipopolysaccharide-stimulated polarization in murine bone marrow derived
macrophages. (Toxicol. Appl. Pharmacol. 2018, submitted)
2. Poole LG, Beier JI, Torres-Gonzales E, Schlueter CF, Hudson SV, Artis A,
Warner NL, Nguyen-Ho CT, Dolin CE, Ritzenthaler JD, Hoyle GW, Roman
J, Arteel GE. Chronic + binge alcohol exposure promotes inflammation and
alters airway mechanics in the lung. (Alcohol. 2018, in press)
3. Hudson SV, Dolin CE, Poole LG, Massey VL, Wilkey DW, Beier JI,
Merchant ML, Frieboes HB, and Arteel GE. Modeling the Kinetics of Integrin
Receptor Binding to Hepatic Extracellular Matrix Proteins. Sci Rep. 2017;
7(1): 12444. PMID: 28963535. PMCID: PMC5622105
4. Poole LG, Dolin CE, Arteel GE. Organ-Organ Crosstalk and Alcoholic Liver
Disease. Biomolecules. 2017; 7(3): 62. PMID: 28812994. PMCID:
PMC5618243
As primary author
5. Dolin CE, Poole LG, Wilkey DW, Isaacs SM, Arteel GE, Rouchka EC, Barati
MT, Merchant ML. Proteotranscriptomics demonstrates chronic moderate
alcohol consumption influences renal cortical oxidant response pathways.
(2019, in preparation)
6. Massey VL*, Dolin CE*, Poole LG, Hudson SV, Siow DL, Brock GN,
Merchant ML, Wilkey DW, and Arteel GE. The hepatic “matrisome”
responds dynamically to injury: characterization of transitional changes to
the extracellular matrix in mice. Hepatology. 2017; 65(3): 969-982. PMID:
28035785. PMCID: PMC5319876. [*co-first authors listed by seniority]
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